



THE DIFFERENTIAL INFLUENCE OF HIV-1 SUBTYPE C,  
NUCLEOSIDE ANALOG RESISTANCE MUTATIONS: K65R, A62V, S68N AND Y115F 




Onyisi Christiana Didamson 
Student Number: 217079876 
 
Submitted in fulfilment of the requirements for the degree of Master of Medical Science in 
Virology, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, 
University of KwaZulu-Natal,  
2019 






The experimental work described in this dissertation was carried out in the Hasso Plattner Research 
Laboratory of the HIV Pathogenesis Programme at the Doris Duke Medical Research Institute, Nelson R. 
Mandela School of Medicine, University of KwaZulu-Natal, Durban, from February 2018 to February 2019 
under the supervision of Michelle Lucille Gordon (PhD).  
These studies represent original work by the author and have not otherwise been submitted in any form for 
any degree or diploma to any other University. Where use has been made of the work of others, it is duly 
acknowledged in the text.                           
Signed:        Date: 13 August 2019 
Onyisi Christiana Didamson (Candidate) 
 
Signed:  Date:  14 August 2019  
 

















I, Onyisi Christiana Didamson, declare that: 
1. The research reported in this dissertation, except where otherwise indicated is my original 
work. 
2.  This dissertation has not been submitted for any degree or examination at any other university. 
3. This dissertation does not contain other persons’ data, pictures, graphs or other information 
unless specifically acknowledged as being sourced from other persons. 
4. This dissertation does not contain other persons’ writing unless specifically acknowledged as 
being sourced from other researchers. Where other written sources have been quoted, then: 
a. Their words have been re-written, but the general information attributed to them has been 
referenced. 
b. Where their exact words have been used, their writing has been placed inside quotation 
marks and referenced. 
c. Where I have reproduced a publication of which I am an author, co-author or editor, I have 
indicated in detail which part of the publication was actually written by myself alone and 
have fully referenced such publications. 
5. This dissertation does not contain text, graphics or tables copied and pasted from the Internet, 
unless specifically acknowledged, and the source being detailed in the dissertation and the 
Reference sections. 
Signed:   Date:  13 August 2019 
Onyisi Christiana Didamson (Candidate) 
 
Signed:  Date:  14 August 2019  
 







Full ethical approval was obtained for this study from the Biomedical Research Ethics Committee of the 
Nelson R. Mandela School of Medicine, University of KwaZulu-Natal (BREC Ref No: BE600/17). 
 
Presentation 
Didamson OC and Gordon ML. Impacts of Tenofovir Selected Mutation of HIV-1 Subtype C on 
Replication Capacity and Tenofovir Susceptibility at the University of KwaZulu Natal, Annual Laboratory 



















My sincere appreciation goes to my supervisor, Michelle Gordon (PhD) for her mentorship, support, and 
understanding through the course of my degree. 
My sincere thanks are due to the HIV Pathogenesis Programme for the privilege and access to use the 
laboratory facilities throughout my laboratory work. 
I would like to thank the University of KwaZulu-Natal, College of Health Sciences and the Poliomyelitis 
Research Foundation for their financial assistance. 
I would like to thank Mrs Keshni Hiramen for her kind laboratory and non-laboratory assistance. 
My appreciation goes to the staff and students of the HIV Pathogenesis Programme. Especially, Ma 
Nothemba, Pholi, Lanish, Mpume, Katlego, Doty, Tayo, Nelly, Msizi, and Zakithi for their kind assistance 
in the laboratory. 
To my colleagues, Khe, Zola, Jade, Simeon and Yolanda, thank you for your morale supports, friendship, 
and assistance. 
My special thanks to my siblings Ruth Yunana, Simon Uzoka, Justina Utebor, Tina Okonkwo, Agatha 
Udoh and Joy Uzoka for their loving support, prayers, constant calls and encouragement. 
My gratitude to my mummy Roseline Uzoka for her continuous prayers and loving care and my aunt Uzoka 
Bridget for her loving support and constants calls. 
To Mr and Mrs Yusuf Audi my parent-in-law, thank you for your support and prayers. Also, my gratitude 
goes to my in-laws, Elisha and Sarah for their constant calls and encouragements, they meant a lot to me. 
God bless you all. 
My loving appreciations are due to my husband Ibrahim Didamson for his love, continuous support, 
patience, priceless sacrifice and for always believing in me. Thank you for taking care of me and the 
children all the way. I am indeed blessed to have you in my life. 
My special thanks to my children Shams and Shim for their prayers, patience, and understanding throughout 





This thesis is dedicated to God for His faithfulness, grace, preservation, provision, and strength upon my 
life through this research. Indeed, He is my Ebenezer. 
Also, is dedicated to my loving husband, children (Shams and Shim), Mum (Roseline Uzoka), and my 






















The use of Tenofovir Disoproxil Fumerate (TDF) for the treatment of HIV-1 infection has been 
recommended for the first-line as well as a second-line antiretroviral regimen in South Africa, due to its 
high antiretroviral activity and low toxicity level. However, the efficacy of the drug could be threatened by 
the emergence of drug resistance mutations. The development of TDF resistance poses a public health 
threat. TDF resistance can be acquired through a selection of the K65R mutation or the K70E mutation 
(though less frequently) under TDF selection pressure. Besides, K65R and K70E mutations, recent studies 
have identified other mutations associated with TDF resistance such as A62V, K65N, S68G/N/D, 
K70E/Q/T, L74I, V75L, and Y115F. These mutations were particularly observed to be in association with 
the K65R mutation and were reported to be more common in HIV-1 subtype C viruses. Also, these 
mutations could cause high-level resistance to TDF, especially when in combination with K65R. However, 
in-vitro studies are required to demonstrate their influence on viral fitness and TDF susceptibility. In this 
study, we investigated the impact of K65R, A62V, S68D, Y115F, and K65R+S68N on replication capacity 
and TDF susceptibility. The reverse transcriptase (RT) region was amplified from a drug-naive HIV-1 
subtype C isolate obtained from a patient enrolled in the Tropism study (BREC: BF088/07) and cloned into 
a TOPO vector using a TOPO TA cloning kit. The HIV-1 RT mutations (K65R, A62V, S68D, Y115F, 
K65R+A62V, K65R+S68D, K65R+S68G, 
K65R+S68N, and K65R+Y115F) were introduced into the TOPO+RTsubC recombinant using the 
Quikchange lightning Multi site-directed mutagenesis kit. Next, recombinant viruses were created by co-
transfection of the mutant RT amplicons and a pNL4-3-deleted-reverse transcriptase (RT) (pNL43∆RT) 
backbone into GXR cells by electroporation. The replication capacity of the mutant viruses was assessed 
using a replication method that utilized a green fluorescent protein (GFP) reporter cell line and flow 
cytometry. We evaluated the replication capacity using the exponential growth curve function in Excel to 
determine the percentage GFP-expressing cells between days 2 and 6. The impact of the mutant viruses on 
susceptibility to TDF was performed in a luciferase-based assay. The 50% inhibitory concentration (IC50) 
was calculated using Graph Pad Prism. Drug susceptibility was expressed as the fold change in IC50 of 
mutant virus compared with the wild type virus. 
Of the 5 TDF- selected mutants analysed: A62V, K65R, and Y115F mutants display a reduction in 
replicative fitness whereas, S68D and K65R+S68N showed high viral fitness. Interestingly, the TDF- 
selected resistance mutations we analysed, showed high susceptibility (A62V, S68D, and Y115F) and 
reduced susceptibility (K65R and K65R+S68N) to TDF. Our findings support the hypothesis that TDF- 
selected mutations only confer reduced susceptibility to TDF. Hence, further study is needed on various 
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Over 77.3 million individuals have been HIV positive following the HIV-1 outbreak, with about 35.4 
million deaths related to AIDS globally. In 2017, 36.9 million people were reported to be having HIV while 
approximately 21.7 million individuals were on antiretroviral treatment worldwide. Approximately 1.8 
million individuals were diagnosed with new HIV infections and  0.94 million died from AIDS-influenced-
illness in the same year (UNAIDS, 2018). Sub-Saharan Africa bears the highest HIV burden globally, with 
about 4.2% of individuals having the virus, representing approximately two-thirds of the HIV global burden 
(UNAIDS, 2018). Within this region, South Africa (where HIV-1 subtype C dominates) has the highest 
HIV-1 burden which is also the highest globally (WHO, 2018). In South Africa, the prevalence rate of HIV 
infection, new diagnosis, and AIDS-linked mortality are 19%, 15%, and 11% respectively. However, the 
KwaZulu-Natal (KZN) province, which is the location of this study has the highest infection with about 
40.8% infected individuals (UNAIDS, 2018). Interestingly, there has also been a huge decrease in new HIV 
infections and AIDS-linked mortality since 2010 by 49% and 29% respectively (UNAIDS, 2018). 
In 2017, South Africa had a total of 7.2 million individuals having HIV, 270000 of newly HIV infected 
individuals and 110000 mortality of AIDS-related illness (UNAIDS, 2018). To combat this epidemic, the 
most effective interventions towards this goal was the initiation of “highly active antiretroviral therapy 
(HAART)” for the prevention and treatment of HIV (UNAIDS, 2016, WHO, 2012). Large-scale 
interventions have been placed among the main global health goals, to eliminate the epidemic spread by 
2030 (UNAIDS, 2016) as well as achieving universal ART access and the UNAIDS 90-90-90 target by 
2020. In 2017, 4.4 million (61%) infected individuals had access to antiretroviral treatment, representing 
20% of individuals on antiretroviral therapy in the world and 47% had their viral load suppressed (SANAC, 
2017, UNAIDS, 2018). 
In the last few decades, great achievements have been made through ART intervention among which 
include: great improvement in the life of HIV-1 individuals; drastic reduction in the mortality and morbidity 
rate of AIDS-associated illness; and huge decrease in mother-to-child HIV-1 spread (Granich et al., 2009, 
UNAIDS, 2016, Weng et al., 2016, WHO, 2012, Williams et al., 2011). However, in spite of these profound 
benefits and the large ART scale-up programme in South Africa, the prolong usage of these ARVs has led 
to the development of both acquired and transmitted drug-resistant mutations that confer cross-resistant and 
limit the benefits of subsequent treatment option (Hamers et al., 2013, Rhee et al., 2015, Sigaloff et al., 
2012, Steegen et al., 2016). The evolution of HIV-1 drug resistance arises due to the following factors: lack 
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of proofreading in the HIV-1 reverse transcriptase (RT) enzyme in the course of replication, high turnover 
HIV-1 of multiplication, increased reservoir of the provirus strains during infection, recombination of 
different DNA sequences affecting the same target cell resulting in a large number of quasi-species and 
rapid evolution under drug selection pressure (Coffin, 1995, Katzenstein, 2006, Li and Kuritzkes, 2013, 
Shafer, 2002). Also, other contributing factors include poor compliance, inadequate drug absorption, a low 
genetic barrier to resistance, and the presence of pre-existing drug resistance mutations. The ultimate effect 
of drug resistance mutations is virologic failure leading to treatment failure (Coffin, 1995, Skhosana et al., 
2015). Studies have reported that during treatment on first-line NRTI/NNRTI based treatment regimens, 
about 10% - 30% of individuals experienced virologic failure (VF) and more than half of these individuals 
acquired drug-resistant viruses (Aghokeng et al., 2014, McMahon et al., 2013, Rhee et al., 2015).  
In 2010, South Africa implemented the use of TDF for both first-line and second-line antiretroviral 
treatment, as well as for pre-exposure prophylaxis in conjunction with the World Health Organization 
(WHO) ART treatment recommendations for adult HIV-1 infection (Bennett et al., 2008, NDOH, 2014, 
WHO, 2013). The effective use of TDF can be limited by the development of drug resistance mutations. 
Studies have identified the K65R mutation as the main TDF resistance mutation (TenoRes-Study, 2016, 
Rhee et al., 2017, HIVBD, 2019). Also, the K70E mutation is an alternative pathway of TDF resistance; 
however, its occurrence is not common (TenoRes-Study, 2016, Rhee et al., 2017, HIVBD, 2019). 
 A previous study observed a greater than 50% incidence of K65R in viruses isolated from Sub-Saharan 
Africa (TenoRes-Study, 2016). Similarly, an increase in the incidence of the K65R resistance mutation has 
been observed in South African TDF treated patients (Skhosana et al., 2015, Sunpath et al., 2012), although 
Hoffmann and colleagues reported a low prevalence of the K65R mutation (Hoffmann et al., 2013). Another 
study showed that K65R was the most commonly transmitted or pre-treatment drug resistance mutation in 
ART-naive individuals in South Africa (Steegen et al., 2016). Furthermore, recent studies have observed 
other mutations “A62V, K65N, S68G/N/D, K70E/Q/T, L74I, V75L and Y115F” commonly found with 
TDF resistance in patients on TDF treatment and are seen to be co-selected particularly with K65R. These 
mutations were discovered to be higher in subtype C compared to subtype B (Maphumulo, 2016, Margot 
et al., 2016, Rhee et al., 2017). Therefore, it is paramount to determine the phenotypic implication of these 
mutations. In this study, we analysed the impact of the following TDF selected mutations: A62V, K65R, 
S68D, Y115F and K65R+S68N of HIV-1 Subtype C on viral replication capacity and susceptibility to TDF. 
1.2 Human Immunodeficiency Virus  
The human immunodeficiency virus (HIV) is “the aetiological agent of acquired immunodeficiency 
syndrome (AIDS)” and dates back in 1983. Since then, the epidemic is yet to be completely eradicated, but 
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rather under manageable control (Sampathkumar et al., 2012). HIV belongs to the class of virus known as 
Lentivirus of the family of Retroviridae and subfamily Orthoretrovirinae (ArbeitskreisBlut, 2016, Klimas, 
2008). HIV is categorised into two, known as HIV-1 and HIV-2 based on genetic features and viral antigen. 
HIV-1 is the most prevalent and account for the global AIDS epidemic. It is also more infective, virulent 
and has high transmissibility rate. While, HIV-2 has lower pathogenic potentials and is mostly confined to 
West Africa due to its lower transmissibility rate (Kanki and Travers, 1994, O’Donovan et al., 2000). 
However, HIV-1 and HIV-2 likewise affect the immune system and develop an illness that compromises 
the immune system (Klimas, 2008, Sampathkumar et al., 2012, Santoro and Perno, 2013). While, in HIV-
2 AID develop at a slower rate, with a higher CD4 count compared to HIV-1 (Esbjornsson et al., 2018, 
Martinez-Steele et al., 2007). 
 HIV has its origin from non-human primate harbouring the retrovirus Simian immunodeficiency virus 
(SIV). The SIV infecting humans represent two different zoonotic transmission sources namely, 
chimpanzee (SIVcpz), and sooty mangabeys (SIVsm) and are closely related to HIV-1 and HIV-2 
respectively (Chavan, 2011, Katzenstein, 2006, Peeters and Sharp, 2000, Sampathkumar et al., 2012). 
Nevertheless, irrespective of not having the same origins, HIV-1 and HIV-2 share in total about 55% 
similarity on the nucleotide level (Li et al., 2015, Motomura et al., 2008). While, on the amino acid level 
about 55% similarity in Gag and Pol, and 35 % similarity Env (Motomura et al., 2008). However, a study 
has reported high genetic divergence between HIV-1 and HIV-2 with more than 50% sequence differences 
in the genes encoding the envelope proteins (Mourez et al., 2013). Also, the replication fitness and 
cytopathicity between the virus types have shown varying outcomes, despite having similar transmission 
routes and target cells (Arien et al., 2005).  
Furthermore, both HIV-1 and HIV-2 have been characterized into groups, subtypes, and recombinant forms, 
with HIV-1 being well described into various groups, subtypes, sub-subtypes and circulating recombinant 
forms. Presently, nine groups denoted as A-I have been described for HIV-2, initially known as subtypes 
(Sauter and Kirchhoff, 2019, Visseaux et al., 2016), with A, B and D as the most predominant group 
(Santiago et al., 2005, Visseaux et al., 2016). Also, some recombination have been seen to be present 
between intergroup, while information on HIV-2 subtype is not available (Santiago et al., 2005, Ibe et al., 
2010, Visseaux et al., 2016), 
1.3 HIV-1 
1.3.1 Groups and Subtypes 
Phylogenetic analysis from different geographical areas have established 4 distinct clades of HIV-1 namely: 
“group M (main), N (new, or non-M, non- O), O (outlier) and P (putative group)”, nevertheless, all manifest 
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the same clinical symptoms (Klimas, 2008, Peeters and Sharp, 2000, Santoro and Perno, 2013, Sharp and 
Hahn, 2011).  The M group which was the first to be isolated in 1983 (Barré-Sinoussi et al., 1983), is the 
major strains found globally, and its account for the worldwide AIDS pandemic (Sharp and Hahn, 2011).  
The second to be isolated was Group O in 1990 and is not as widespread as the group M (De Leys et al., 
1990) with about 1% of the worldwide HIV-1 infection. It is highly confined to Cameroon and surrounding 
countries (Peeters et al., 1997).  
The third to be discovered was group N in 1998 from an individual originating from Cameroon (Simon et 
al., 1998), and it is not as disseminated as group O; with just 14 cases of infection reported (Vallari et al., 
2010). While, the fourth to be identified was group P in 2009 from a 62-year-old Cameroonian woman 
residing in France (Plantier et al., 2009). Presently, only two strains of group P have been described, and 
are closely related phylogenetically; however, proof of any connection between the two strains is lacking 
(Vallari et al., 2011). The use of molecular clock analysis has postulated that a common ancestor of HIV-1 
major groups moved into the human population in the mid-20th century and it is considered to have 
originated from chimpanzees and/or gorillas (Katzenstein, 2006, Korber et al., 2000). While group N, O 
and P are restricted to Central Africa (Sharp and Hahn, 2011).  
HIV-1M group is characterized by vast divergent subtypes and circulating recombinant forms (CRFs). 
Phylogenetically, the group M viruses are classified into pure subtypes and CRFs. There are currently nine 
subtypes namely: “A, B, C, D, F, G, H, J, and K”, with A and F subtypes further sub-classified into A1-A6 
and F1and F2 respectively (Foley et al., 2016). The while circulating recombinant forms (CRFs) result 
when an individual is infected by multiple HIV-1 subtype variants either by coinfection or superinfection, 
giving rise to recombinant viral genome made up of regions from each of the diverse subtypes. The 
recombination formed is a consequence of template switching and the reverse transcriptase switches 
between the two templates in the course of the reverse transcription process. Therefore, sequences relating 
to a CRF have similar recombination split points in the genome. If there are huge epidemic transmission 
and dissemination of these new recombinants within a population, they are considered being circulating 
variants and are categorized as CRF (Peteers, 2000, Neher and Leitner, 2010). Also, the variant must be 
identified from two unrelated persons and completely sequenced (Carr et al., 1998). When more than three 
subtypes are present the designation “cpx” (complex) is employed (McCutchan, 2006).  
Presently, over 98 different CRFs have been registered in the Los Alamos National Laboratory 
(www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html), and they account for 16.7% of all HIV 
infections in the world (Hemelaar et al., 2019). The characterization of HIV-1 into subtypes and CRFs 
confirm HIV diversity and also describes the several cross-species distributions seen in Africa, where the 
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initial HIV-1 isolate was derived (Katzenstein, 2006). HIV-1 subtypes vary in nucleotide sequence by 30% 
-40% in the envelope gene, 8–10% variation in the pol/gag genes, 20% variation within subtypes, and differ 
by 25 and 35% across subtypes (Peeters and Sharp, 2000, Santoro and Perno, 2013, Hemelaar et al., 2006).  
1.4 Global distribution of HIV-1  
HIV-1 subtype B is the dominating subtype in America, Europe and Australia, CRF-01_AE dominates in 
Asia, and CRF02_AG in Western Africa (Figure 1.1). While the largest HIV-1 subtypes and CRFs variation 
is found in Central Africa, the origin of HIV. HIV-1 subtype C is prevalent in southern Africa, the horn of 
Africa, India and China. (Figure 1.1) (Maartens et al., 2014, Tebit and Arts, 2011, Bbosa et al., 2019). 
 
Figure 1.1: Global distribution of HIV-1 subtypes, CRF and URF. Taken from Bbosa et al., (2019). 
Abbreviations: CRF – circulating recombinant form; URF – unique recombinant form. 
A recent update in the global distribution of HIV-1 subtypes, CRF and URF by Hemelaar et al showed  that 
subtype C is the more dominant type (46.6%), then by subtype B (12.1%), subtype A (10.3%), subtype G 
(4.6%), subtype D (2.7%) and any of subtypes F, H, J or K (0.9%). The CRF02_AG was prevalent in 7.7% 
of the global population with CRF01_AE in 5.3% of the population, with other recombinants accounting 




1.5 HIV-1 Structure 
HIV-1 is a spherical enveloped retrovirus with a diameter of about 120nm that consists of the following 
components namely, the viral envelop, matrix, capsid, nucleocapsid, and the viral genome. The viral 
envelope is bi-lipid layers consisting of two envelop proteins, glycoprotein (gp) gp120 and gp41 which 
facilitate the attachment and fusion of the virus to the affected cell to initiate infection (figure 1.2). These 
envelope proteins are potential target against HIV-1 infection (Rajarapu, 2014). Within, the viral envelope 
is the matrix, which surrounds the capsid (p24), consists of the p17 viral protein that maintains the integrity 
of the virion particle (figure 1.2). The capsid (p24) encloses the nucleocapsid (p7/p6) that is tightly bound 
to the viral genetic material (RNA). The nucleocapsid also contains enzymes consisting of, reverse 
transcriptase, protease ribonuclease and integrase required for viral replication process (Rajarapu, 2014).   
1.6 HIV-1 genome organization 
HIV-1 genome is made up of about 9720 base pairs and nine genes, flanked by the long terminal repeat 
(LTR) at the 5’ and 3’ ends (figure 1.3) (Frankel and Young, 1998, Gallo et al., 1988, Muesing et al., 1985). 
The nine genes consist of three structural genes and six accessory genes. The structural genes consist of: 
“group-specific antigen (gag), polymerase (pol) and envelope (env)” that encode vital information crucial 
for the generation of new viral particles.  The gag gene reading frame encodes four structural proteins that 
form the viral core: “the capsid (CA) p24, the matrix (MA) p17, the nucleocapsid (NC) p7 and p6 protein” 
(King, 1994, Mushahwar, 2007). The second reading frame, the pol genes codes for the viral enzymes, 
reverse transcriptase (RT, p55), ribonuclease H (RNase H, p15), or RT plus RNase H (p66), protease (PR, 
p12), and integrase (IN) (Frankel and Young, 1998, Votteler and Schubert, 2008) and are target for 
antiretroviral drugs (Levy, 2007). The Env viral glycoprotein the third reading frame codes for surface 
gp120 and transmembrane gp41 (King, 1994, Mushahwar, 2007, Frankel and Young, 1998). The six 
accessory genes consist of: negative regulatory factor (nef), regulator of expression of virion particles (rev), 
trans-activator of transcription (tat), viral protein R (vpr), viral infectivity factor (vif), and viral protein 
unique (vpu), that encode for proteins that regulate the potential of HIV-1 to enter a cell, generate of viral 
particles, or initiate pathogenesis (Frankel and Young, 1998). Vpx (virus protein x) in place of vpu, is seen 
in HIV-2, is proposed to be accountable for the low pathogenic nature of HIV-2 (Vicenzi and Poli, 2013). 
The long terminal repeat (LTR) at each end of the HIV-1 genome has a binding site which facilitates and 




Figure 1.2: General features of HIV-1 virion. Taken from Rajarapu (2014).  
Abbreviations: NC- Nucleocapsid; CA- Capsid; RT- Reverse transcriptase; IN- Integrase; PR- Protease and 




Figure 1.3: Genomic organization of HIV-1. Taken from Rajarapu (2014). 
1.7 Infection of human cells and HIV-1 Replication cycle 
The interaction of a protein-protein complex characterizes the first steps of HIV infection. The surface 
glycoprotein (gp) 120 of the well-formed HIV particles attach to the CD4 receptor of the host cell1. Upon 
fusion one of the two CD4 receptor: “C-C chemokine receptor type 5 (CCR5) or C-X-C chemokine receptor 
type 4 (CXCR4)” is activated which accelerates the release of the gp41 protein for efficient membrane 
binding, resulting in the merging of the viral envelope and the CD4 receptor into the host cell 
(ArbeitskreisBlut, 2016). The viral core enters the cytoplasm and un-coats releasing the diploid viral RNA 
genome and “the viral enzymes (RT, IN and PR)” (Rajarapu, 2014). The RT enzyme transcribes the single-
stranded viral DNA into two strands of proviral DNA.  
The proviral DNA is transferred into the nucleus and is incorporated into the host genome by the IN enzyme 
(Rajarapu, 2014). This stage of integration concludes the HIV infection of the cell and the maintenance of 
continuous infection (ArbeitskreisBlut, 2016).  The new provirus can reproduce, as the host cell replicates 
fusing existing cellular transcription mechanism which results in the synthesis of new RNA and RNA that 
codes for the viral proteins. The viral proteins and components merge at the surface of the host surface and 
                                                          




are spliced by the protease enzyme into functional units. The new complete viruses are assembled and bud 
off from the surface of the host cell into extracellular space, acquiring an envelope and attachment spike 
(Rajarapu, 2014, Klimas, 2008). Following infection with HIV, about two days is needed to produce the 
first progeny viruses from the infected cell with a daily turnover rate of 108- 109 viral particles. This is due 
to the error in the RT proofreading activity. It is postulated that under one replication cycle under no 
antiretroviral drug, an evolutionary rate of 1 in 104 of nucleobase in a genome do occur, resulting in 
genetically distinct, but closely related viruses circulating in the body known as the quasispecies (Santoro 
and Perno, 2013).  While under antiretroviral drug pressure, rapid virus turnover together with a high 
mutation rate is the main mechanism behind the development of HIV variants with antiretroviral drug 
resistance (Santoro and Perno, 2013). 
 
Figure 1.4: HIV-1 Replication Cycle. Taken from (Pomerantz and Horn, 2003). 
1.8 HIV-1 Reverse Transcriptase 
The HIV-1 RT enzyme converts the virus single-stranded RNA into two strands of DNA that are 
incorporated into the host genome (Sarafianos et al., 2009, Shafer, 2002). The HIV-1 RT has two catalytic 
sites, the N-terminal polymerase and the C-terminal RNase H. The N-terminal polymerase carries out two 
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enzymatic roles which are, RNA- and DNA-dependent DNA polymerization. While the C-terminal RNase 
H splits RNA from RNA/DNA hybrid to release the new DNA strand required as a template for DNA 
synthesis. These two catalytic sites of RT, work together to generate a double-stranded linear DNA from 
RNA (Sarafianos et al., 2009, Li et al., 2016, Huang et al., 1998). The HIV-1 RT is a heterodimer composing 
of a p66 and p51 subunit. These subunits are products of the Gag-Pol polyprotein precursor cleavage 
through the action of the viral protease (PR). The p66 subunit is comprised of 560 amino acids and is made 
up of three domains: the polymerase, RNase H and the connection domain that joins the polymerase and 
the RNase H domain (Sarafianos et al., 2009, Shafer, 2002, Kohlstaedt et al., 1992). The polymerase domain 
further consists of four subdomains: fingers (amino acid (aa) residues 1–85 and 118–155), palm (86–117 
and 156–236 amino acid residues), thumb (237–318 amino acid residues), and connection (319–426 amino 
acid residues) (Sarafianos et al., 2009). While the p51 subunit comprised of 449 amino acids of the pol gene 
and is catalytically non-functional but provide the platform for the enzymatic function of the p66 subunit 
(Shafer, 2002).  The p51 subunit also consists of four subdomains and has a similar sequence: “fingers, 
palm, thumb, and connection”, although, the orientation is quite different from the p66 subunit (Kohlstaedt 
et al., 1992, Sarafianos et al., 2009).  
 




1.9 HIV-1 Antiretroviral (ARV) Drug 
 The first ART to be authorized by the USA Food and Drug Administration (FDA) was zidovudine (AZT) 
in the 1980s (Brook, 1987, Ezzell, 1987). In the 1990s, the HIV-1 treatment was transformed by the 
development of inhibitors of two key HIV-1 enzymes (RT and PR) and the advent of combined 
antiretroviral therapy (cART) for efficient and long-lasting treatment (Arts and Hazuda, 2012, Gulick et al., 
1997, Staszewski et al., 1996). The combined therapy which consists of three different antiretrovirals 
(ARVs) known as HAART (highly active antiretroviral therapy) has profound benefits. These benefits 
include the following: a) decline in the mortality and morbidity rate of HIV-1 infection and AIDS, changing 
the deadly disease into a controllable persistent illness, and consequently increasing the life span of an HIV 
infected individual; b) drastic curtailment of viral replication; c) reduction of plasma HIV-1 viral load below 
identification threshold; and restoration of the immune function (Arts and Hazuda, 2012, Staszewski et al., 
1996). Following this development and advantage, HAART was immediately incorporated for clinical use 
and treatment of HIV individuals who are initiating treatment newly as well as treatment-experienced 
individuals. 
Currently, the Food and Drug Administration (FDA) has authorized over 30 antiretroviral drugs (ARVs) 
for clinical use (DHHS, 2018). These antiretroviral drugs target several key viral processes and are 
categorised into seven classes. These include “nucleoside/nucleotide reverse transcriptase inhibitors 
(NRTIs)”, “non-nucleoside reverse transcriptase inhibitors (NNRTIs)”, “protease inhibitors (PIs)”, “fusion 
inhibitors”, “inhibitors of co-receptors”, “integrase strand transfer inhibitors (INSTIs)” and “a CD4 post-
attachment inhibitor” (Markham, 2018). Four of these classes of the ARVs target the function of the three 
key viral encoding enzymes, RT, PR and IN, while the fusion inhibitors and inhibitors of co-receptors block 
fusion and/or the entry of the virus to the host cells (Arts and Hazuda, 2012, De Clercq, 2009). See Table 











Table 1.1:  Major classes of ARVs and their mode of actions 




Block the post-attachment 
process of the viral particle to 




Prevent the fusion of the virus 
to their target cells 
Enfuvirtide (T-20) 
CRI Interfere with the entry of HIV 
in the target cell 
Aplaviroc (APL) and Maraviroc (MVC) 
 NRTIs DNA)chain terminators and 
inhibit reverse transcription 
Zidovudine (ZDV), Didanosine (ddI), Zalcitabine 
(ddC), Stavudine (d4T), Lamivudine (3TC), 
Abacavir (ABC), TDF (TDF) and Emtricitabine 
(FTC) 
NNRTIs Bind to the hydrophobic 
pocket inhibiting the RT 
enzyme 
Nevirapine (NVP), Efavirenz (EFV), Etravirine 
(ETV), Rilpivirine (RPV) and Doravirine (DOR), 
Integrase 
inhibitors (IN) 
Inhibit the attachment of 
proviral DNA to host cell 
genome 
Raltegravir (RAL), Elvitegravir (EVG), 
Dolutegravir (DTG and Bictegravir (BIC). 
Protease 
inhibitors (PIs)  
Target the viral enzyme 
required for cleavage of viral 
precursors and final assembly 
of viral particles 
Saquinavir (SQV), Indinavir (IDV), Ritonavir 
(RTV), Nelfinavir (NFV), Amprenavir (APV), 
Lopinavir (LPV), Atazanavir (ATV), 
Fosamprenavir (FPV), Tipranavir (TPV) and 
Darunavir (DRV). 
Abbreviations: NRTIs -Nucleoside reverse transcriptase inhibitors; NNRTIs- Non-Nucleoside reverse 
transcriptase inhibitors.                                             
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1.10 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
Non-nucleoside reverse transcriptase inhibitors bind to the amino acids inside the hydrophobic binding loop 
within reverse transcriptase leading to a conformational change around the active site, hence interfering 
with the chemical step that is crucial for DNA synthesis (Clavel and Hance, 2004, Sarafianos et al., 2009, 
Shafer, 2002). Conformational analyses of HIV-1 RT have revealed that the hydrophobic binding loop does 
not occur in the absence of the NNRTIs.  In the event of the NNRTIs opening the pocket, it limits some of 
the movements of the enzyme that are crucial for DNA synthesis. Hence DNA synthesis cannot occur in 
the absence of the movements (Clavel and Hance, 2004, Kohlstaedt et al., 1992, Sarafianos et al., 2009). 
Examples of NNRTIs that have been approved by the FDA for use are NVP, EFV, ETR, RPV, and DOR 
(DHHS, 2018). 
1.10 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) 
Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are deoxyribonucleic acid (DNA) chain 
terminators that inhibit the additional elongation of the proviral DNA during reverse transcription. There 
are eight NRTIs that have been approved by the FDA, seven nucleoside analogues: Abacavir (ABC), 
Didanosine (ddI), Zalcitabine (ddC), Stavudine (d4T), Zidovudine (AZT), Emtricitabine (FTC), 
Lamivudine (3TC) and one nucleotide analogue: TDF. These NRTIs form the backbone of the first-line 
regimen in most countries (Shafer, 2002, Cihlar and Ray, 2010).  This study will focus more on TDF and 
the resistance mutations associated with this drug. 
These nucleoside and nucleotide analogues are prodrugs that requires activation by the host cellular 
enzymes through a process called phosphorylation. The phosphorylated NRTIs that was converted to the 
active triphosphate form compete with the cells naturally produced substrate (deoxynucleoside 
triphosphates, dNTPs) for insertion into the newly formed complementary DNA (Shafer, 2002). This 
prevents additional elongation of the DNA chain, owing to the absence of the 3’OH group that is essential 
for the formation of the phosphodiester bond during  complementary cDNA synthesis, resulting in DNA 
chain termination (Das and Arnold, 2013). Nevertheless, the effectiveness of these drugs is jeopardized by  
the emergence of HIV-1 drug resistance mutations (Shafer, 2002). 
1.12 Mechanism of HIV-1 Drug Resistance  
HIV-1 drug resistance is described as the presence of viral strains that can decrease drug effectiveness in 
relation to the wild-type viruses (Shafer, 2002). These evolve through the following factors: HIV-1 reverse 
transcriptase (RT) proofreading error in the course of replication, high turnover rate of the HIV-1 
multiplication, increased reservoir of provirus strains during HIV-1 infection, genetic hybridization due to 
virus of difference sequence affecting the similar  cell resulting in large number of quasi-species and rapid 
15 
 
evolution under drug selection pressure (Clutter et al., 2016, Coffin, 1995, Katzenstein, 2006, Li and 
Kuritzkes, 2013, Shafer, 2002). Other contributing factors are non-compliance, low genetic barrier 
resistance, treatment interruption due to drug stock out and drug interaction (Clutter et al., 2016, Hamers et 
al., 2013). Furthermore, the evolution of drug resistance relies on the rate at which the virus continues to 
replicate under sub-optimal therapy, the ability of the virus to gain some mutations and their impact on the 
drug activity and growth fitness (Clutter et al., 2016, Shafer, 2002). Conversely, drug-resistant viruses occur 
daily in treatment-naïve individuals although these strains are hardly detected due to reduced viral fitness 
compared to drug-susceptible strains when there is selective drug pressure (Perelson and Ribeiro, 2013). 
Most drug resistance mutations of clinical significance are non-polymorphic as they emerge only under 
selective drug pressure and are rarely detected in untreated individuals (Clutter et al., 2016, Tang and 
Shafer, 2012).  
Drug resistance mutations (DRMs) can develop due to either a single DRM or by multiple DRMs and can, 
therefore, be grouped into primary and secondary mutations. Primary DRMs reduce drug susceptibility by 
themselves while secondary (accessory) DRM improves the fitness of primary DRMs or promote reduced 
susceptibility (Clutter et al., 2016, Shafer, 2002, Tang and Shafer, 2012). However, this classification is not 
strictly defined as a mutation that is major for one drug can be minor for another drug (Shafer, 2002). 
However, both primary and secondary mutations in the RT gene can limit the efficacy of reverse 
transcriptase inhibitors (RTIs) (namely, NRTIs and NNRTIs). 
1.13 Mechanisms of NNRTI resistance 
Mutations in RT nevertheless can develop resistance to the NNRTIs. The hydrophobic binding pocket 
harbours the majority of the NNRTI resistance mutations. The commonly observed resistance mutations in 
individuals on NNRTIs therapy are K103N and Y181C. Additional NNRTI resistance mutations seen in 
individuals include: “L100I, K101E, V106A, V179D, Y188L, G190A, and P236L”. The occurrence of 
these mutations can be alone or in combination (Sarafianos et al., 2009). However, the main challenges 
with NNRTIs are the low genetic barrier to resistance (one mutation in the binding site can sufficiently 








Table 1.2: Overview of NNRTIs resistance mutations. Taken from  (HIVBD, 2019). 
 
Abbreviations: Cons- Consensus; DOR-doravirine; EFV- efavirenz; ETR- etravirine; RPV- rilpivirine and 
NVP- nevirapine. 
1.14 Mechanisms of NRTI resistance 
The occurrence of NRTI resistance involves two main mechanisms, primer unblocking and a discriminatory 
mechanism (Clavel and Hance, 2004, Shafer, 2002, Shafer and Schapiro, 2008). The primer unblocking 
mechanism involves mutations that cause the resumption of reverse transcription and DNA synthesis by 
enhancing the excision of chain-terminating NRTIs, thereby facilitating primer unblocking through 
pyrophosphorolysis. The mutations that act through this mechanism include: “M41L, D67N, K70R, 
L210W, T215F/Y, K219Q/E (called the thymidine analogue mutations-TAMs)” and the T69 insertions 
seen with multi-nucleoside and most of the secondary mutations.  These primer unblocking mutations have 
less effect on polymerase activity (Clavel and Hance, 2004, Shafer, 2002, Shafer and Schapiro, 2008). 
While in the discriminatory mechanism, the mutations favour the incorporation of the cells’ natural dNTP 
substrate than the NRTIs during polymerization, preventing the addition of the NRTIs to the growing DNA 
chain (Sarafianos et al., 1999a, Shafer and Schapiro, 2008, Clavel and Hance, 2004, Shafer, 2002). These 
mutations occur at or close the NRTIs binding site on the RT gene, and often tend to reduce the catalytic 
polymerase activity in-vitro (Clavel and Hance, 2004, Shafer, 2002). Mutations that act through the 
discriminatory mechanism (blocking NRTIs incorporation) includes, M184V/I, K65R, L74V, Q151M 
(multi-nucleoside mutation) (Clavel and Hance, 2004, Shafer and Schapiro, 2008). The M184V mutation 
develops in viruses in patients receiving 3TC or FTC therapy (Arts and Hazuda, 2012), while K65R emerges 
with TDF, ddC, ddI, d4T, and ABC treatment (Margot et al., 2002). Usually, K65R hardly develops in 
individuals on AZT-containing regimens as a result of its antagonism to the TAMs (Parikh et al., 2006). In 
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the presence of K65R, TDF susceptibility is restored by the M184V mutation; hence individuals that fail 
3TC or FTC with M184V on TDF rarely develop K65R (Deval et al., 2004). 
The RT function and viral replicative fitness can decrease due to several primary and secondary NRTI 
mutations (or combination of both) (Quinones-Mateu and Arts, 2006). Though reduced replicative fitness 
due to NRTI resistance mutations have a possible clinical advantage, a high level of resistance can occur 
under drug selection pressure due to an accumulation of more mutations. While under no drug selection 
pressure, the loss of replicative fitness caused by drug resistance mutations is restored by the accumulation 
of secondary mutations (Arts and Hazuda, 2012). 
Table 1.3: Overview of NRTIs resistance mutation. Taken from (HIVBD, 2019) 
 
Abbreviations: Cons- consensus; 3TC-lamivudine; FTC- emtricitabine; ABC- abacavir; TDF-tenofovir; 
AZT- Zidovudine; TAMs- Thymidine analogue mutations and MDR- multidrug resistance mutations. 
1.15 Tenofovir Disoproxil Fumerate (TDF) 
The TDF is a nucleotide analogue RT inhibitor and a very effective antiretroviral agent for treating HIV-1 
infected individuals (both those starting treatment newly and already on treatment) (Margot et al., 2002, 
Squires et al., 2003). It has a durable intracellular half-life, less toxic and is formulated as a once-daily 
single tablet (Gallant et al., 2006). The TDF treatment in individuals having drug resistance can result in a 
decrease of about 0.6log10 HIV-1 RNA copies/ml of plasma by week 24 (Squires et al., 2003) and it is also 
active against most resistant strains associated with NRTI (Miller et al., 2001).  
However, the effectiveness of TDF can be threatened when treatment failure emerges due to non-
compliance and HIV drug resistance mutations.  “Treatment failure is defined as the emergence of disease 
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following HAART introduction”.  Failure can be evaluated by the following indicators: a) clinical indicator 
(the presence of new opportunistic infections); b) immunological indicator (low CD4 count); or c) virologic 
indicator (viral RNA reappearance above the detection limit of 200copies/ml (Aldous and Haubrich, 2009). 
Viral load measurement has been recommended as the ideal measure for evaluating and detecting 
therapeutic failure since 2010 (WHO, 2010). 
Therefore, in areas where viral load measurement is not accessible, response to antiretroviral therapy (ART) 
and treatment failure can be evaluated by clinical examination as well as immunologic examination (WHO, 
2010). A study has observed that patients who failed first-line therapy especially for a prolonged period 
have a higher probability of experiencing suboptimal therapy, develop rapid drug resistance and fail 
treatment (Todd et al., 2006). Thus, timely identification of TDF resistance mutations is crucial as it can 
assist in predicting treatment efficiency and prevent resistance, which is cost-effective at the long run.  
1.16 TDF resistance Profile 
HIV-1 subtype C infection in patients, on which treatment is failing, develop TDF resistance 2.44 times 
more compared to individuals with other subtypes. In addition, individuals on nevirapine are 50% more 
likely to develop TDF resistance compared to individuals on efavirenz. Likewise, individuals on lamivudine 
have 50% likely chance to develop TDF resistance compared to individuals on emtricitabine (TenoRes-
Study, 2016). Tenofovir resistance is often associated with the K65R signature mutation and is proposed to 
rapidly appear in in-vitro selection in subtype C compare to other subtypes (Brenner et al., 2006, Invernizzi 
et al., 2009). 
Studies have reported that in low- and medium-income countries (LMICs), 20% - 60% of patients with 
incomplete viral suppression develop DRM with TDF based first-line treatment (Rhee et al., 2017, 
TenoRes-Study, 2016). There are two routes to TDF resistance: the K65R and the K70E/Q routes. The rate 
of emergence of K65R and K70E/Q mutations in patients with virologic failure is about 40% and 10% 
respectively (TenoRes-Study, 2016). The combination of K65R and K70E results in high replication 
capacity impairment and as such are hardly seen occurring together (Kagan et al., 2007).  
However, when alone, K65R has high resistance to TDF as well as diminished replication capacity 
compared to K70E (Kagan et al., 2007, Melikian et al., 2012, Shafer, 2017, Sluis-Cremer et al., 2007). In 
patients failing TDF based first-line treatment, mutations that have been found include S68G/N/D, Y115F, 
A62V, L74I, K70N/T/G, K65N, and T69 deletions with prevalence a of  20%, 12%, 10%, 6%, 3.2% 0.7% 
and 0.3% respectively (Shafer, 2017, TenoRes-Study, 2016). These mutations are higher in subtype C 
compared to subtype B (Margot et al., 2016, Rhee et al., 2017). Some of these mutations are frequently 
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found with K65R (Rhee et al., 2017). However, the implication of these mutations on TDF in subtype C 
sequences needs further phenotypic investigation. 
Viruses harbouring K65R is found to have a high fitness cost when in association with A62V and S68G 
(Svarovskaia et al., 2008), while Y115F is found to diminish TDF activity (Margot et al., 2006b, Melikian 
et al., 2012). Greater than 5- fold resistance to TDF are often found when in association with type 1 
thymidine analogue mutations (TAM). On the other hand, TDF-selected DRMs when occurring together 
with cytosine-analogue DRMs M184V/I confer about 2-fold resistance to TDF (Margot et al., 2006b, 
Melikian et al., 2012, Shafer, 2017). Most TDF-associated DRMs have been shown not to cause resistance 
to AZT (Shafer, 2017). However, cross-resistance to other NRTIs have been commonly observed with 
TDF-associated DRMs. “K65R/N, Y115F, L74I, and K70E/Q/N/T/G” cause cross-resistance to Abacavir 
(ABC) (Margot et al., 2006b, Melikian et al., 2012). While K65R causes less resistance to 3TC and FTC 
when compared with M184V/I (Margot et al., 2006b, Melikian et al., 2012, Shafer, 2017).  
1.17 Lysine (K) 65 Role in HIV-1 RT 
The lysine (K) 65 is very crucial in polymerization fidelity, drug resistance and is located in the nucleotide-
binding pocket, the location for drug resistance mutations, leading to reduced sensitivity of most nucleoside 
RT inhibitors (NRTIs). K65 constitutes part of the nucleobase binding site found between the β3 and β4 
chain that make up the dynamic loop of the finger domain of the HIV-1 RT, which is essential for the 
polymerization process. K65 also supports the incorporation and proper alignment of the inbound dNTP 
into the growing DNA chain via the formation of a salt bridge between the epsilon-amino group of K65 
and the γ phosphate of the inbound nucleotide. However, in the presence of K65R, the nucleotide-binding 
interaction greatly alters the γ-phosphate (Garforth et al., 2014, Huang et al., 1998). 
1.18 Mechanism of K65R Mutation 
K65R arise from a G-to-A change (AAA to AGA) and was initially found in individuals who were treated 
with the 2’-3’dideoxynucleoside inhibitor, ddC (Zhang et al., 1994) and have a broad resistance to other 
NRTIs with exception of AZT (Deval et al., 2004, Margot et al., 2002, Wensing et al., 2017). K65R distorts 
the conformation of the nucleotide incorporated in the polymerase functional site, while still maintaining 
the firmness of the same nucleotide necessary for polymerization (Zhang et al., 1994). K65R reduces the 
steric flexibility of the RT as a result of the arrangement of the guanidinium sheets of the R65 and R72 
bases (Sarafianos et al., 1999a). In the K65R mutant RT, stacking of the guanidinium of the arginine with 
the incoming nucleotide renders the R65 and R72 residues inflexible. This steric inflexibility is proposed 
to be the mechanism behind the reduced polymerization rate seen in K65R mutant virus, by favouring the 
incorporation of dNTP over NRTIs, which alter the uptake of ATP (Das et al., 2009). 
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1.19 K65 Resistance Mutation and Subtype C 
Studies have shown that non-subtype B viruses treated with d4T/ddI, d4T/3TC or TDF/3TC often develop 
the K65R mutation (Doualla-Bell et al., 2006, Hawkins et al., 2009, Wallis et al., 2010). Clinical studies 
have reported increase treatment failure and increase development of the K65R mutations in HIV subtype 
C individuals than in subtype B receiving TDF (Skhosana et al., 2015, Sunpath et al., 2012, TenoRes-Study, 
2016, Theys et al., 2013). The above finding is consistent with the study by (Smit et al., 2017), which 
reported that patients experiencing treatment failure with HIV-1 subtype C viruses are highly susceptible 
to develop K65R mutations with double fold prevalence than other subtypes.  Furthermore, in-vitro studies 
have shown that K65R developed more quickly in subtype C than in subtype B, in the presence of increasing 
concentrations of TDF (Brenner et al., 2006, Coutsinos et al., 2010, Garforth et al., 2014, Theys et al., 2013) 
(Theys et al., 2013). 
This variation is likely due to the following mechanisms (figure 1.4): the nature of the subtype C RNA 
template (Coutsinos et al., 2011), distinctive polymorphisms at codons 64(AAA), 65(AAG) and 66 (AAG), 
pausing activities at codon 65 due to a poly-adenine region that permits wrong arrangement, insertions, 
deletions, strand chain and recombination, thereby promoting the development of K65R during reverse 




Figure 1.6: The increased selection of K65R in subtype C. The selection of K65R is initiated by the 
poly-adenine stretches at position 63 and 65. The stop occurs in poly stretches in position 65 (Brenner and 
Coutsinos, 2009). 
However, other studies could not determine variations in response rates between subtype B and C due to 
the above mechanism (Xu et al., 2009, White et al., 2002, Günthard and Scherrer, 2016); rather they found 
that the variation was due to differences in demographics and clinical characteristics such as adherence, 
standard of care and delay in switching after treatment failure leading to the accumulation of drug resistance 
mutations (Günthard and Scherrer, 2016, White et al., 2016). 
1.20 HIV-1 Drug-Resistant Testing 
The occurrence of HIV-1 drug resistance mutations can be monitored and investigated through drug 
resistance testing (Granich et al., 2009). Resistance testing is an essential tool for proper care of HIV 
infected individuals particularly when changing their treatment plan in the event of incomplete virologic 
response, as this helps in the identification and measurement of drug resistance (Gunthard et al., 2019, 
Hirsch et al., 2008, Wensing et al., 2017). Resistance testing can also guide in deciding the right regimen 
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in the individuals newly initiating treatment, considering the increasing rate of transmitted drug-resistant 
viruses (Haubrich, 2004b). Presently, there are two types of HIV-1 drug resistance testing: genotypic 
resistance assay and phenotypic drug resistance testing (Schutten, 2006, Sen et al., 2006, Shafer, 2002). 
1.21 Genotypic Assay  
Genotypic resistance assays detect mutations that cause the loss of drug susceptibility by DNA sequence 
analysis of the gene of interest in the virus genome. The sequence generated is compared with the sequence 
of the reference control virus to identify variations (Schutten, 2006, Sen et al., 2006). Genotypic tests 
involve the following steps: viral RNA extraction from plasma, reverse transcription and amplification of 
the cDNA by PCR. The amplicons are then sequenced on an automated DNA sequencer. This generates 
complete data on the viral genotype (Schutten, 2006). There are two approaches to genotypic assay: 
commercial assay kits and the in-house protocol. 
Commercially available genotypic resistance tests kits include: “HIV-1 GenotypR PLUS (Specialty 
Laboratories), TRUGENE HIV-1 genotyping test (Visible Genetics), VircoGEN II (Virco), ViroSeq HIV 
genotyping system (PE Applied Biosystems), GeneSeq (ViroLogic), HIV-1 Mutation Analysis (Focus 
Technologies), HIV ViroTYPE (Rheumatology Diagnostics Laboratory), GenoSure (LabCorp and Virco), 
and HIV-1 Genotype (Quest Diagnostics)”  (Liu and Shafer, 2006, Sen et al., 2006). These kits are also 
packaged with interpretation tools; the two widely used commercial genotypic assays authorized by the 
FDA are: “TRUGENE HIV-1 genotyping test (Visible Genetics) and ViroSeq HIV genotyping system (PE 
Applied Biosystems)” (Schutten, 2006). 
In-house methods are mostly used by laboratories due to its low cost. On the other hand, the in-house 
method is faced with inadequate assay validation and lack of general standardization. Yet, there is not much 
difference between the two approaches as shown by blinded quality assurance programmes (Hirsch et al., 
2008). Both commercial assay kits and the in-house approaches use Sanger’s sequencing approach for the 
identification of HIV-1 resistance mutations. Although Sanger-based genotypic assays are the most 
commonly used methods, they are limited in their sensitivity as they can only identify variants above 15%- 
20% of the viral population, omitting low minority variants (viral quasispecies) that may occur at low 
abundance of the viral population (Fox et al., 2014, Gibson et al., 2014, Halvas et al., 2006, Palmer et al., 
2005). 
Studies have demonstrated that these minority variants can impact significantly on patient treatment 
outcome (Cozzi-Lepri et al., 2015, Li et al., 2013a). There are technologies available that can detect these 
minority variants for as low as about 5% and above. These include: “next-generation sequencing” (Ram et 
al., 2015), “allele-specific-PCR (ASPCR, oligonucleotide ligation-based assays (OLA)”, “a Ty1/HIV-1 RT 
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hybrid system (TyHRT)”, “single-genome sequencing (SGS)”, and “a line probe assay (LiPA)” (Halvas et 
al., 2006, Metzner, 2006). Another shortcoming of the genotypic assay is the inability to identify different 
unusual mutational patterns and interpreting multiple groups of mutations (Puertas et al., 2012, Shafer, 
2002). However, genotypic testing is preferred than the phenotypic assay because of the following benefits: 
it is inexpensive, short analytical time, precise evaluation, easy to perform, readily available online 
interpretation algorithms (Hirsch et al., 2008, Puertas et al., 2012, Sen et al., 2006). 
1.21.1 Interpretation of Genotypic Resistance Assay 
Interpretation of genotypic resistance result is essential as there are diverse drug resistance mutations 
(DRMs) in complicated combinations (Gunthard et al., 2019). There are several tools available to guide in 
the proper interpretation of genotypic results. These tools consist of several collections of resistance 
algorithms and are constantly reviewed to give outlines and explanation of resistance mutations for each 
antiretroviral drug (HIVBD, 2019, Shafer, 2017, Wensing et al., 2017). Two types of genotypic test 
interpretation system exist; the rule-bases systems and the algorithm based or machine-learning system 
(Doring et al., 2018, Gunthard et al., 2019).  
The rule-based system relies on set rules and expertise input. It is the widely used interpretation system as 
it takes into account other forms of information. This system is reproducible, transparent and informative; 
however, it is prone to bias (Gunthard et al., 2019). Examples of rule-based interpretation system include 
“the French National Agency for Research on AIDS and Viral Hepatitis”, “Rega”, “HIV Genotypic 
Resistance- Algorithm Deutschland”, “AntiRetroScan”, and “the Stanford HIV Drug Resistance Database” 
(Doring et al., 2018, Gunthard et al., 2019, Liu and Shafer, 2006, Puertas et al., 2012). In this system the 
virus is grouped into three; “susceptible”, “intermediate resistant” and “resistant” (Liu and Shafer, 2006, 
Sen et al., 2006). While the Stanford HIV Drug Resistance Database and AntiRetroScan have five levels of 
resistance such as “susceptible”, “potential low-level resistance”, “low-level resistance”, “intermediate 
resistance”, and “high-level resistance” (Liu and Shafer, 2006, Sen et al., 2006). 
The algorithm-based interpretation system utilizes statistical models and machine learning algorithms. A 
classic example of the algorithm-based interpretation system includes the geno2pheno (Liu and Shafer, 
2006) and the SHIVA system (Doring et al., 2018). The difference between the geno2pheno and the SHIVA 
software algorithm-based interpretation system relies on the approach in which the data set, and the 
machining learning algorithm is applied. For instance, vector regression is used in geno2pheno, while 
SHIVA uses random forest (Doring et al., 2018). 
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1.22 Phenotypic resistance assay.  
Phenotypic assays quantify the concentration of drugs required to prevent HIV growth in cell culture 
(Hirsch et al., 2008, DHHS, 2018). These assays assess the correlation of the replication of a HIV-1 test 
sample to the reference strains (wild-type virus) in drug concentration. Similar to the genotypic assay, the 
phenotypic assay uses PCR to amplify the HIV-1 gene of interest. These assays generate a recombinant 
virus by inserting the gene of interest derived from a patient into a reference molecular clone lacking the 
equivalent gene(s) of interest (Clutter et al., 2016, Hirsch et al., 2008, Sen et al., 2006). This recombinant 
virus contains an indicator (reporter) gene and is used in-vitro to infect host cells in culture. The growth of 
the recombinant virus in the presence/absence of ARVs can be determined by a single cycle phenotypic 
assay or a multiple cycle phenotypic assay (Dykes and Demeter, 2007). The activity or the expression of 
the reporter gene at varying concentration is a measure of the viral replication and is compared with a 
wildtype HIV strain’s replication capacity (Hirsch et al., 2008, Shafer, 2002). 
1.22.1 Types of Phenotypic Assay 
There are two commercially available phenotypic assays: PhenoSense™ (Monogram Biosciences) (a single 
round phenotypic assay) and AntivirogramTM (Virco) (a multiple-cycle phenotypic assay) (Hertogs et al., 
1998, Petropoulos et al., 2000, Sen et al., 2006). Both assays are recombinant based and they both amplify 
the gene of interest from HIV-1 RNA derived patient plasma via polymerase chain reaction (PCR). 
However, the approached in which the amplified product is introduced into the deleted recombinant 
molecular HIV-1 clone backbone differs; the Phenosense assay employs ligation while Antivirogram 
employs homologous recombination (Zhang et al., 2005). For both assays, cell line are infected with a 
standardized amount virus, and virus replication competency is determined in the presence and absence of 
varying concentrations of ARVs. 
In the PhenoSense™ (Monogram Biosciences) assay, the recombinant HIV-1 vector lacking the 
corresponding gene of interest has another deletion in the envelope gene (env) and insertion of luciferase 
gene insertion. The env deletion enables a single round of infection of the recombinant virus, while the 
luciferase acts as a reporter gene. Drug susceptibility and replication capacity are determined through 
luciferase production in the test sample relative to the reference strain (Sen et al., 2006, Zhang et al., 2005). 
In the AntivirogramTM (Virco) assay, the recombinant virus is cultured in multiple rounds of infection.  
Drug susceptibility and replication capacity are determined through cell killing in the cell culture by 
measuring the expression of the tetrazolium dye production which relates to the number of live cells 
available following multiple rounds of infection (Sen et al., 2006, Zhang et al., 2005). The sensitivity and 
reproducibility of Phenosense assay are higher than Antivirogram (Zhang et al., 2005). 
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1.22.2 Interpretation of Phenotypic Resistance assay 
The results obtained from phenotypic assays are presented as fold change (FC) which is the drug 
concentration that suppress viral multiplication by 50% (IC50) of the test sample divided by the IC50 of 
the wild-type reference strain (Haubrich, 2004a, Clutter et al., 2016, Hirsch et al., 2008, Parkin et al., 2004a, 
Sen et al., 2006, Haubrich, 2004b) (Figure 1.5).  
 
Figure 1.7: Interpretation of phenotypic test. Drug concentration requires to prevent virus growth in-
vitro to 50.0% (50.0% inhibitory concentration, IC50) compare to a wild-type (WT) reference virus. Taken 
from Haubrich, (2004).  
Interpretation of Phenotypic assay is essential, due to variation in fold change susceptibility of each ARV 
that exist. Hence, to establish the relevance of FC in the susceptibility threshold or cut-off values are used 
and are categorized into three cut-offs (Parkin et al., 2004a, Gunthard et al., 2019). 
1. Technical cut-offs- this measures the reproducibility of reference HIV-1 strain sensitivity to an 
ARV drug. However, this does not portray the true intrinsic difference observed in a patient without 
treatment (Hirsch et al., 2008, Parkin et al., 2004a, Sen et al., 2006).  
2. Biological cut-offs: this measures the natural variation in IC50 of various wild-type strain obtained 
from HIV-1 infection individuals without treatment (Hirsch et al., 2008, Parkin et al., 2004a, Sen 
et al., 2006). 
3. Clinical cut-offs: these are cut-offs values obtained from clinical trials in relation to patient 
responses to treatment. It consists of two cut-offs: the lower cut-off (intermediate resistance) which 
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is the lowest fold decrease at which slight resistance in the drug activity is observed; and the upper 
cut-offs (full resistance) at which there is complete drug inactivity (Hirsch et al., 2008, Parkin et 
al., 2004a, Sen et al., 2006).   
Phenotypic assays are conducted on individuals presented with complicated forms of drug resistance 
mutations patterns and hence are more reliable than genotypic assays. However, discrepancies in the use of 
cut-off mark limits it uses (Hirsch et al., 2008).  
1.23 HIV-1 Replication Capacity/ Fitness 
HIV-1 replication capacity or fitness is the tendency of a virus to multiply in a given condition and this can 
be influenced by several interwoven factors such as host factors (e.g. genetic makeup, targeted cells and 
immune response), viral factors (e.g. HIV-1 replication cycle which involves several stages) and 
antiretroviral therapy factors (Daar, 2005, Nicastri et al., 2003, Nijhuis et al., 2001).   The measure of HIV-
1 replication fitness in-vitro can be an efficient tool in determining prognosis or treatment outcome in-vivo.  
Therefore, replication capacity or fitness assays can be used to know when to begin therapy and change a 
failing regimen which is a prognostic tool for an antiviral outcome. A general feature of replication capacity 
assays is the relativity of the mutant virus to the control strain (Miao et al., 2008).  
1.23.1 Measuring HIV-1 Replication Capacity 
There are different in-vivo and in vitro methods available for the measurement of viral replication capacity. 
In-vivo methods are presumed to be more significant. On the other hand, they are hard to carry out and it 
depends on the amount of virus measured (Daar, 2005).  Although an animal model can be used to measure 
viral fitness in-vivo, it still does not present the exact condition of the patient in-vivo. In-vivo fitness is 
determined by measuring viral kinetics in plasma. In-vitro methods measure the intrinsic potential of the 
virus to multiply relative to the reference control strains.  This method can be achieved by evaluating the 
enzymatic activity of the virus (Back et al., 1996), in-vitro replication with a complete virus, growth 
competition assays or recombinant strains having a gene of interest of the virus (Kellam and Larder, 1994, 
Quinones-Mateu and Arts, 2006).   
1.23.2 Measure of HIV-1 Replication Fitness In-Vitro 
There are numerous methods available for measuring viral fitness in-vitro, these include “growth 
competition versus parallel infections, whole virus versus recombinant virus assays, multiple cycle versus 
single-cycle assays, reporter gene versus a viral gene or gene product to monitor virus growth and the use 
of cell lines versus primary human cells” (Dykes and Demeter, 2007, Nijhuis et al., 2001, Quinones-Mateu 
and Arts, 2006) (Table1.4). 
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Table 1.4: Description of replication capacity assay. taken from (Dykes and Demeter, 2007). 
 
1.24 Project Rationale 
Tenofovir is “a nucleotide analogue RT inhibitor introduced for the treatment of HIV infection”(Squires et 
al., 2003). However, the efficacy of the drug can be limited by the evolution of drug resistance mutations. 
TDF resistance can be acquired through the K65R mutation or the K70E mutation (though less frequently) 
under TDF selection pressure. The development of TDF resistance poses a public health threat, since TDF 
is currently used in the first-line regimen as well as in the second-line regimen in South Africa, where HIV-
Methods Brief description 
Parallel infection assay Sample and control are cultured in different media. Easy to perform but less 
sensitive, subject to experimental differences. 
Growth competition 
assay 
Sample and control are cultured together in the same medium. Can easily 
detect minute changes in fitness compared to parallel infections. 
Single-cycle replication 
assay 




Test is performed in several rounds of infection with the env gene intact 
Whole virus assay Test is conducted using complete viral genome derived from patient PBMCs 
Recombinant virus 
assay 
Test is conducted by inserting the gene of interest derived from a patient 
sample into a molecular clone. 
Direct measure of virus 
replication 
Viral growth is determined by measuring a viral protein e.g. p24 
Use of reporter gene Determine the viral growth by measuring the expression of a reporter gene 
produced by the recombinant virus 
Use of cell line Test is conducted in an engineered T-cell line 
Primary human cell Test is conducted in primary human cells 
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1 subtype C predominates. Studies from our group and others have revealed additional mutations such as 
“A62V, K65N, S68G/N/D, K70E/Q/T, L74I, V75L and Y115F” frequently found in association with 
patients under TDF treatment and were higher in subtype C compared to subtype B (Maphumulo, 2016, 
Rhee et al., 2017). However, their influence on TDF susceptibility in HIV-1 subtype C warranted further 
investigation. 
1.25 Project Aim and Objectives 
Aim 
1. To determine the impact of TDF-selected mutants (K65R, K65R/S68N, A62V, S68D/G/N and 
Y115F) of HIV-1 subtype C on replication capacity and TDF susceptibility. 
Objectives 
1. To generate TDF-selected mutants (K65R, K65R/S68N, A62V, S68D and Y115F) of HIV-
1subtype C using site-directed mutagenesis. 
2. To demonstrate the effects of TDF-selected mutants (K65R, K65R/S68N, A62V, S68D/G/N and 
Y115F) of HIV-1 subtype C on replication capacity and TDF susceptibility. 
Hypothesis 
 It is expected that under drug selection pressure, TDF-selected mutations will impact on replication 
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Generation Tenofovir-Selected Resistance Mutations of HIV-1 Subtype C 
2.1 Introduction 
Tenofovir disoproxil fumarate (TDF) is an approved constituent of first- and second-line antiretroviral 
regimens in the WHO HIV treatment guidelines (WHO, 2010), and is an effective antiretroviral agent for 
treating both newly and treatment-experienced HIV-1 infected individuals (Margot et al., 2002, Squires et 
al., 2003). It has durable half-life within the cell, is less toxic and is administered as a once-daily one tablet 
(Gallant et al., 2006).  
TDF is unique among the other approved NRTIs by exhibiting an effect against a broad range of NRTI 
resistant strains (Miller et al., 2001). However, the use of TDF can be compromised when treatment failure 
emerges due to non-compliance and the development of drug resistance mutations which result from staying 
on the failing regimen for a prolonged period  (Todd et al., 2006). Identification of TDF resistance mutations 
can help to predict treatment efficacy and thus allow efficient drug use, stop resistance and maintain cost-
effectiveness of the National ARV treatment plan.  
Besides the commonly selected K65R mutation associated with TDF resistance in HIV-1 subtype C, 
studies have also reported other mutations such as “A62V, K65N, S68G/N/D, K70E/Q/T, L74I, V75L 
and Y115F” (Maphumulo, 2016, Rhee et al., 2017, TenoRes-Study, 2016). However, their phenotypic 
impact needs further investigation. This study investigated the most frequently observed mutations 
associated with TDF resistance such as K65R, A62V, S68G/N/D, Y115F and combinations of these 
mutations with K65R. In this chapter, we concentrate on the generation of TDF-selected resistance 
mutations of HIV-1 subtype C virus using site-directed mutagenesis. 
2.2 Materials and Methods 
2.2.1 Study Sample 
A plasmid containing the RT region of an HIV-1 subtype C treatment naïve sample (obtained from patient 
PKE4N from the tropism study (BREC Ref No: BF088/07) was used for the site-directed mutagenesis 
reactions. The UKZN Biomedical Research Ethics Committee authorized the current study (Ref No: 
BE600/17). The RT region was amplified from this plasmid to confirm the presence of the amplicon and 
prepare for the site-directed mutagenesis reaction. 
2.2.2 Amplification of HIV-1 Reverse Transcriptase (RT) 
PCR was performed utilizing a TaKaRa Ex Taq HS enzyme kit (Takara Biotechnology, Japan). For the 
PCR, chimeric forward and reverse primers that were specifically corresponding to NL4-3 backbone on 
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each side of RT were used, resulting in an overlap that was necessary for transfection. All reagents except 
the enzyme were thawed and vortexed for five seconds to mix. The master mix was prepared as shown in 
Table 2.1  
Table 2.1: Reaction components and volumes for the PCR 
Reaction component Volume per reaction(µl) Final Concentration 
PCR Graded water 37 - 
10X Ex Taq Buffera 5 1X 
dNTP mixture (2.5mM each) 4 (200µM) 
Forward primer(10µM) 0.8 (0.16µM) 
Reverse primer ((10µM) 0.8 (0.16µM) 
TaKaRa Ex Taq (5 U/ul) 0.25 1.25U 
plasmid DNA product 2 - 
Total Volume 59.85  
a. Ex Taq buffer contained 20mM MgCl2, resulting in a 2 mM final concentration 





P66_F 5’_ CTGCGGACATAAAGCTATAGGTACAGTATTAGTAGGACC 
TACACCTGTCAACATAATTGGAAGAAATCTGTTGACTCAGATT 
GGCTGCACTTTAAATTTT _3’ 





Primers sequence was a gift from Dr Mark Brockman (Simon Fraser University, Canada).  
Table 2.3: Thermocycler conditions for the PCR. 
Segment Cycle  Temperature (°C) Time Step 
1 1 94 2 minutes Initial activation step 
2 40 94 30 seconds Denaturation 
  60 30 seconds Annealing 
  72 2 minutes Extension 
3 1 72 7minutes Final extension 




2.2.3 Gel Electrophoresis  
 Gel electrophoresis was performed to verify the PCR product. A 1% agarose gel was made by adding one 
agarose tablet (0.5g) (Bioline, USA) to 50 ml of 1X TBE buffer (Sigma-Aldrich, USA) (component: 89mM 
Tris base, 89mM Boric acid, 2 mM EDTA) in a 200 ml flask. The flask was kept for approximately 10 
minutes at room temperature and then heated in a microwave till the agarose was completely melted. The 
solution was cooled to the touch and poured into a casting tray. The gel was allowed set for 20 to 30 minutes. 
It was then placed in an electrophoresis tank; 1X TBE buffer was poured into the tank until the gel was 
fully immersed. Two microlitres (µl) of each sample and two μl of gel loading dye (Sigma-Aldrich, USA) 
were mixed, then loaded into the wells in the gel. The gel loading dye was prepared by adding one μl of gel 
red (Biotium, USA) to 50μl of loading buffer. A one kb ladder (Invitrogen, Life Technologies, Carlsbad, 
CA) (Figure 2.1) was included on the gel. The gel was processed at 120 V, 500 mA for 40 minutes on an 
Electrophoresis Power Supply- EPS 301 (Amersham Biosciences, Sweden). The gel was viewed using the 
Chemi Doc MP Imaging System (BioRad) (Figure 2.2). The negative control was examined for any visible 
bands apart from primer dimer <100bp, as bands >100bp to check for any contamination. The size of the 
amplified product was checked against the ladder; the expected size was 1.879kb. The product was stored 
at -20°C until purification. 
2.2.4 Amplicon Clean up 
The PCR product was cleaned using the QIAmp PCR purification kit (Qiagen, Valencia, CA), as per the 
manufacturer’s instructions. The purified product was measured using nanodrop to determine the 
concentration of the products for Cloning. 
2.2.5 Cloning into pCR™II-TOPO® Vector 
This PCR product was ligated into a TOPO PCR II vector from the TOPO TA Cloning kit (Invitrogen, 
USA) for use in site-directed mutagenesis. A ligation reaction was performed following the manufacturer’s 
directions. Briefly, two µl of the purified product was added to a ligation mixture, along with one µl of the 
vector. The reaction was incubated at room temperature for 30 minutes. 
2.2.5.1 Transformation 
Top10 competent cells from the TOPO TA cloning KIT (Invitrogen, USA) were transformed with the 
ligation mixture, as per manufacturer’s instructions. Briefly, two μl of the ligation reaction was added to 
one vial of TOP10 competent cells (50μl) and incubated on ice for 30 minutes. The mixture was exposed 
to 30 seconds of heat shock at 42° C and placed immediately on ice for two minutes. Two hundred and fifty 
μl of S.O.C media (supplied with the kit) was added to each reaction mixture. After a one-hour incubation 
at 37°C with shaking at 230 rpm, the ligation mixtures were plated out onto pre-warmed agar containing 
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ampicillin (100 μg/ml). The plates had been prepared 30 minutes prior with 40μl of 5-bromo-4-chloro-3-
indolyl-β-D-galactopyranoside (X-Gal) (50 mg/ml solution) to allow for blue/white selection.  
Blue/white selection was used to select clones containing the insert. The site of ligation of the PCR product 
is found in the coding sequence of the lacZα gene of the pCR™II-TOPO® Vector. This gene expressed the 
enzyme β-galactosidase. The activity of this enzyme on X-Gal generates blue colonies. Successful ligation 
of an insert into the vector interrupts this gene, preventing the production of the blue precipitate, producing 
white colonies. For this study, ten white clones were selected at random for screening by PCR. 
2.2.6 Verification of the PKE4N clone by colony PCR and sequencing  
2.2.6.1 Colony PCR  
Colony PCR, followed by gel electrophoresis, was used to determine the presence of the RT-containing 
insert in the TOPO plasmid as follows: ten colonies were picked from the transformation plate, touched on 
another LB-ampicillin agar plate (master plate) to keep a record of the colonies, and added in 10 μl PCR 
graded water. This suspension was briefly vortexed and boiled in a thermocycler at 95°C for five minutes. 
Two μl of this solution was used as the template DNA for the screening PCR. TaKaRa Ex Taq HS version 
PCR kit (Takara Biotechnology, Japan) was used for the PCR as described in section 2.2.2.  
A 1% agarose gel was used to confirm the presence of a PCR product as described in section 2.2.3. The gel 
was examined using the Chemi Doc MP imaging system (BioRad). PCR products were purified from 
colonies positive for a PCR product using the QIAmp PCR Purification kit (Qiagen, Valencia, CA), as per 
manufacturer’s instructions.  
2.2.6.2 Sequencing of the colony PCR product 
After the products were quantified, they were diluted to 20ng/μl using PCR graded water. Direct sequencing 
of the PCR amplification products was conducted using the BigDye Terminator v3.1 cycle sequencing 










Sequence (5’ – 3’) HXB2 
Positions 
PolM4 CTATTAGCTGCCCCATCTACATA 3870 ← 3892 
PolM0 TCCCTCAGATCACTCTTTGGCA 2251→ 2272 
PolM1 GTTAAACAATGGCCATTGACAGA 2610 → 2632 
PolMG ATTGAACTTCCCAGAAGTCTTGAGTT 2798 ← 2823 
PolM8 CTGTATATCATTGACAGTCCAG 3302 ← 3323 









   
 
Figure 2.1: Layout of primers used to sequence the HIV-1 RT. Eight primers were used to sequence the 
reverse transcriptase region of HIV-1. 
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A master mix was made in separate 0.2ml tubes for each primer and comprised the reagents outlined in 
Table 2.5. 
Table 2.5: Reagents and volume used to make the sequencing reaction master mix    
Reagent Volume per reaction (µl) Final Concentration 
PCR graded water 1.6 - 
5X Sequencing buffer 2 1X 
BigDye Terminator 
ready reaction mix 
0.4 - 
Primer 3.2pmol/µl) 1 0.32µM 
Total 5 - 
   
 
Five μl of each master mix was aliquoted into a 96 well optical plate (Applied Biosystems, CA.USA) and 
five μl of the diluted sample was added into each well according to the designated plate layout. The plate 
was sealed with adhesive foil, gently vortexed and centrifuged to collect droplets. The adhesive foil was 
then removed and replaced with a rubber mat which was secured using an applicator to ensure all wells 
were properly sealed. The plate was then placed in the thermocycler and run under the conditions listed in 
Table 2.6. 
Table 2.6: Thermal cycling conditions used for the sequencing reaction.    
Segment Cycle Temperature(°C) Time Step 
1 1 96 1 minutes Initial denaturation 
2 35 96 10 seconds DNA denaturation 
50 5 seconds Primer Annealing 
60 4 minutes Primer Extension 
-  4 ∞ Hold 
                                                                                                                     
The sequencing products were purified immediately following temperature cycling. To each well, one μl 
of EDTA was added, followed by 26 μl of a 1 in 26 solutions of 3M sodium acetate in 100% ethanol. The 
plate was covered by foil, briefly vortexed and centrifuged at 3000 x g for 20 minutes. The plate was 
carefully taken out from the centrifuge, inverted onto a folded paper towel and centrifuged at 150 x g for 
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one minute to eliminate the liquid. Immediately following this step, 35 μl of ice-cold ethanol was added to 
each well, the plate was then centrifuged at 3000 x g for five minutes. Once again, the plate was carefully 
taken out from the centrifuge, inverted onto a folded paper towel and centrifuged at 150 x g for one minute. 
The plate was dried at 50°C for five minutes and kept at -20°C. Before sequencing, the dried pellets were 
re-suspended in 10μl formamide and denatured at 95°C for three minutes. Samples were put into the ABI 
3130 Genetic Analyzer (Applied Biosystems, California). Resulting chromatograms were viewed in Bioedit 
v.7.0.5.3 (Ibis Biosciences, An Abbott Company, CA, USA).  
The colony verified to contain the correct RT PKE4N TOPO clone sequence was then inoculated into three 
ml LB-ampicillin broth (100μg ampicillin per one ml broth) followed by incubation at 37 °C and 250 rpm 
for two hours. This culture was then used to inoculate 100 ml of fresh LB-ampicillin broth, at the same 
concentration, which was incubated overnight at 37 °C and 250 rpm. The RT PKE4N clone plasmid was 
then purified from these bacterial cells by a maxi-prep procedure (Qiagen) according to the manufacturer’s 
instructions.  
2.2.7 Site-Directed Mutagenesis 
The principle of the Agilent QuikChange Lightning Multi Site-Directed Mutagenesis Kit (Agilent, 
Technologies) is shown in the figure 2.2 below.  
2.2.7.1  Selection of Mutants 
Mutations used for this study were selected based on the most prevalent mutations associated with TDF 
treatment in subtype C (A62V, K65R, S68G/N/D, and Y115F) as indicated by a previous master’s student 
(Maphumulo, 2016) and the literature (Rhee et al., 2017).  
2.2.7.2 Mutant Primer Design 
Mutant primers were created employing the web-based Quikchange Primer Design Program accessible 
online at www.agilent.com/genomics/qcpd.  
The mutant primer design was based on the following criteria:  
1. Both the mutant primer sequences had the designated mutations and bind to the same sequence of the 
complementary strands of the plasmid.  
2. Primers were between 25 and 45 bases long with a melting temperature of ≥78°C.  
3. The desired mutation was in the centre of the primer sequence with 10-15 bases of the original sequence 
on either side.  






Figure 2.2: Overview of the QuikChange Lightning Multi Site-Directed Mutagenesis method. (Taken 
from the QuikChange Lightning Multi Site-Directed Mutagenesis Kit instruction manual). 
 
The primers were designed specifically for the PKE04N TOPO clone containing a subtype C drug naïve 
sequence lacking any resistance-associated mutations in reverse transcriptase; the appropriate segment was 
selected and uploaded into the above website mentioned. The molecular features of the PKE04N TOPO 
clone can be seen in Figure 2.3. Table 2.7 shows the mutations needed to generate the designated amino 
acid sequences of the selected variants, standard desalting purified oligonucleotide primers were ordered 
















Figure 2.3: Molecular features of the PKE04N TOPO clone containing the RT region from patient 
PKE04N of the tropism study. The PKE04N clone was used as a template to generate all mutants. 
Labels P66_F and P66_R indicate the binding position of PCR primers. Image generated with 
pDRAW 32 (AcaClone_Software).  
Table 2.7: Mutations required to generate the desired amino acid sequences of the selected variants 
Mutanta Primer Sequenceb (5' to 3') HXB2 
Position 
K65R ATATAACACTCCAGTATTTGCCATAAAAAGGAAGGACAGTACTAAG 2714→2759 




Y115F ATTAGATGTGGGGGATGCATTTTTTTCGGTTCCTTTAGATG  2873→2913 
S68G TATTTGCCATAAAAAAGAAGGACGGTACTAAGTGGAGGAAATTAGTA  2728→2774  
S68N ATTTGCCATAAAAAAGAAGGACAATACTAAGTGGAGGAAATTAGTAG 2729→2775 
a. In order, to create the mutation combinations K65R_A62V, K65R_S68D, K65R_S68G, 
K65R_S68N, K65R_Y115F, independent primers were not utilized, instead, primers designed to 
create the single mutants were used in combination in the site-directed mutagenesis reaction.  
b. The table contains the forward primer sequences (5’ – 3’ direction) and the reverse primer 
sequences are the reverse complements of the forward primers. The mutated codon in each primer 




2.2.7.3 Mutagenesis Reaction  
The PKE04N TOPO plasmid was mutated using the Quikchange® Lightning Multi Site-Directed 
Mutagenesis kit (Agilent Technologies, California, USA) as per manufacturer’s instructions with relevant 
primers containing mutations of interest. Briefly, a PCR reaction for both mutant viruses and positive 
control was prepared as per Table 2.8. Each PCR reaction was cycled in a thermocycler using the following 
parameters: 95°C for two minutes, 30 cycles of  95°C for 20 seconds, 55°C for 30 seconds and 65°C for 
two minutes and 54 seconds followed by a five-minute cycling at 65°C and a two-minute hold at 37°C. 
Following the completion of the PCR cycle, one μl of Dpn1 was added to each tube and incubated at 37ºC 
for five minutes to digest parental DNA.  
Table 2.8: Summary of PCR reaction mix components for both sample and control mutagenic 
reactions, using the QuikChange lightning site-directed mutagenesis kit. 
Component  Sample (μl)  Control (μl)  Final concentration  





2.5  2.5  1x  
Quiksolution  0.75  0  -  
Forward Primer  1  1  100 ng  
Reverse Primer  1  1  100 ng  
Control primer mix  0  1  Proprietary, no 
information in kit*  
dNTPs  1  1  Proprietary, no 
information in kit* 
QuikChange enzyme 
blend  
1  1  1 U/μl  
ds-DNA template 
(PKE04N in TOPO)  
1  0  100 ng/ μl  
ds-control plasmid  0  1  Proprietary, no 
information in kit* 
Total 25 25  
*: the stock concentration was not provided, hence the final concentration could not be determined. 
However, the required volume was used as specified in the protocol that came with the kit. 
2.2.7.4 Transformation of the XL-Gold ultra-competent cells  
XL10-Gold ultra-competent cells (Agilent) were utilized for transformation according to the 
manufacturer’s instructions. Briefly, cells were removed from -80°C freezer and placed on ice to thaw for 
five minutes. A total of 45 μl of cells and two μl of beta-mercaptoethanol were incubated on ice for 10 
minutes. Next DpnI treated DNA from the mutagenesis reaction one point two (1.2) μl was added and 
incubated on ice for 30 minutes. The reaction mixture was subjected to a 30-second heat pulse at 42°C and 
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immediately placed on ice for two minutes. Preheated S.O.C media (250μl) was added to each reaction and 
incubated at 37°C with shaking at 230 rpm for one hour. Afterwards, 100 μl of the transformation reaction 
was plated on LB-ampicillin agar plates which had 40 μl of 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-gal) and 10 μl of 10 mM isopropyl-1-thio-β-D-galactopyranoside (IPTG), which as 
a whole served for easy identification of colonies that were efficiently transformed (i.e. white colonies 
showed efficient transformation while blue colonies were not efficiently transformed). Plates were 
incubated overnight at 37ºC for at least 16 hours.  
2.2.7.5 Mutant screening  
After incubation, five single white colonies were picked and touched to a master-plate before being boiled 
at 95ºC in 10 μl of PCR water. The master-plate was incubated overnight at 37ºC for at least 16 hours and 
stored at 4ºC. The DNA from the boiled colony was amplified by RT- PCR, as described in section 2.2.6.1, 
and sequenced (described in section 2.2.6.2), to confirm the presence of the correct mutation.  
Following the confirmation of the inserted mutation the corresponding colony from the preserved master-
plate was picked and cultured in LB-broth at 37ºC for 16 hours. Mutant plasmid DNA was then purified 
from the colonies confirmed to contain the correct mutant sequence employing the Qiagen maxi-prep 
procedure as per the manufacturer’s instructions. DNA was quantified using the nanodrop and aliquots were 
kept at -80ºC. 
2.2.8 Preparation of CEM-GXR25 cells  
The “CEM-GXR25 green fluorescent protein (GFP) reporter T-cell line “(i.e. GXR cells was donated by 
Dr Mark Brockman) is replication-competent as they have the CD4 receptor and express the CXCR4 and 
CCR5 co-receptors. They also have a GFP expression cassette, which enhances the detection of infected 
cells using flow cytometry.  
A frozen aliquot (i.e. 1 ml) of about one million GXR cells (stored in dimethylsulfoxide [DMSO], Sigma) 
was taken from a liquid nitrogen freezer (Custom Biogenics Systems, Romeo, USA) directly into a 
preheated 37ºC water bath. The tube of cells was gently agitated in the water bath until the contents were 
thawed. Afterwards, the tube of cells was transferred into a T25 flask (Corning-Costar, New York, USA) 
having four ml of pre-warmed R10 culture medium and incubated at 37ºC and 5% CO2 for 24 hours in a 
humidified Heraeus incubator (Thermo Scientific). R10 media comprised of RPMI-1640 (Sigma), 
supplemented with 50 U/ml penicillin-streptomycin (Gibco, New York, USA), 10 mM N-2-hydroxyethyl 
piperazine-N’-2ethanesulfonic acid (HEPES; Gibco), 2 mM L-glutamine (Sigma) and 10% foetal bovine 
serum (FBS; Gibco).  
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After 24 hours, the contents of the T25 flask was transferred into a 15 ml falcon tube and centrifuged at 
1,500 rpm for 10 minutes to remove DMSO. Cells were then re-suspended in one ml of pre-warmed R10 
and transferred into a T25 flask containing nine ml of pre-warmed R10. The flask was then incubated at 
37ºC and 5% CO2 for a further 24 hours. Following incubation, cells were counted by adding 10 μl of 
thoroughly mixed cell culture to 10 μl of trypan blue (Bio-Rad, Hercules, USA). A total of 10 μl of this 
mixture was inserted into a TC20 cell counting slide (Bio-Rad) which was subsequently loaded into a TC20 
automated cell counter (Bio-Rad). The output of the TC20 cell counter was the cell concentration (i.e. 
cells/ml). The volume of cell culture used to obtain a required number of cells was calculated as follows:  
Volume of cell culture (ml) = number of cells required ÷ cell concentration (cells/ml)  
Cells were kept at a concentration of 250 000 cells/ml in a final volume of 30 ml in a T75 flask (Corning). 
Cell growth was monitored every second day and if not used for experiments, 80% of the cell culture was 
removed and replenished with fresh pre-warmed R10. Cells were maintained for a maximum of two months, 
after which time a new aliquot of GXR cells was thawed and prepared for use. 
2.2.9 Generation of Chimeric Viruses 
2.2.9.1 RT amplification by PCR  
The purified mutant PKE04 TOPO clone was amplified using the TaKaRa Ex Taq HS enzyme kit (Takara, 
Shiga, Japan) and the set of 100 nucleotides (which are chimeric forward and reverse primers that 
specifically correspond to NL4-3 backbone on each side of RT to generate an overlap necessary for 
transfection). Two PCR mixtures of 50 μl were prepared for each sample as described in section 2.2.2. 
Agarose gel (1%) electrophoresis was used as described in section 2.2.3 to visualize the resulting PCR 
fragment of 1.879 kb. 
2.2.9.2 pNL4-3Δ RT plasmid digestion  
The pNL4-3ΔRT plasmid (donated by Dr Mark Brockman) was used to generate the mutant viruses. The 
pNL4-3ΔRT plasmid glycerol stock (in STBL3 cells) was taken from -80 ºC freezer, thawed on ice and 
30μl was added to a mixture of Luria-Bertani (LB) (Sigma Aldrich, St Louis, USA) broth and ampicillin 
(100 ml of LB broth and 100 μl ampicillin). This was incubated in a shaking incubator at 37ºC and 230 rpm 
for 16 hours. The plasmid was extracted and purified using the Plasmid Maxi Kit (QIAGEN) as per the 
manufacturer’s instructions and quantified using a nanodrop spectrophotometer (Thermo Scientific, 
Delaware, USA). The quantified plasmid was aliquoted and stored at -80ºC. The purified plasmid was then 
digested with BstEII (New England Biolabs, USA) to obtain a linear DNA fragment. Digestion was 
conducted on the morning of the co-transfection experiment to minimize the re-ligation of the restriction 
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site. The digestion reaction was prepared as shown in Table 2.9 and incubated in a water bath at 60°C for 
2 hours.  
Table 2.9: BstEII digestion reaction. 
Reagent component Volume 
Plasmid (pNL43ΔRT) 10μg 
10X Buffer  1/10 reaction volume 
100X BSA  1/100 reaction volume 
BstEII Enzyme 10U/ul 2 U/μg plasmid 
Sterile Water Makeup to the final desired volume 
 
2.2.9.3 Co-transfection of the RT insert into CEM-GXR25 cell  
The RT fragment was co-transfected with the linearized pNL4-3Δ RT plasmid into CEM-GXR25 cells. For 
the co-transfection steps, the CEM-GXR25 cells were counted using an automated TC20 cell counter (Bio-
rad, South Africa) ensuring the viability of greater than 80%. For each mutant, four million cells were 
resuspended in 300μl of R10 medium, 90μl of RT PCR product and 10 μg digested plasmid was added to 
an electroporation cuvette and mixed. Samples were electroporated at 250 volts and 950μF. The contents 
were then rested in the electroporation cuvette at room temperature for five minutes. Using a Pasteur pipette, 
the contents were added to a T25cm flask containing nine ml of R10 medium, one million cells and 5μg/ml 
of polybrene (Sigma- Aldrich). The flasks were placed in an incubator at 37°C, 5% CO2. On day five, five 
ml of fresh R10 medium was added to the culture.  
On day seven, the percentage of GFP positive cells was measured using flow cytometry on a FACS Calibur 
(BD Biosciences, San Jose, USA). Afterwards, on every second day, two ml of culture was removed of 
which one ml was prepared for flow cytometry and the remaining one ml discarded. The culture was then 
replenished with two ml of fresh R10 medium. When cells reached ~30% infection, the virus in the culture 
supernatant was harvested. 
2.2.10 Monitoring viral growth by flow cytometry   
To determine percentage infection, one ml of culture was placed in cluster tubes (Corning Costar) and 
centrifuged at 1500 x g for 10 minutes to pellet cells. The supernatant was discarded, and the pellet was 
vortexed for a few seconds. Cells were fixed in 200 μl of 2% paraformaldehyde (PFA) and vortex. The 
CEM-GXR25 cells were gated and data for GFP positive cells were acquired, using flow cytometry. 
Cultures above the threshold of 0.05% GFP+ cells were considered positive for infection. 
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2.2.11 Harvesting of Virus  
The viruses were harvested when ~30% infection was attained. The whole culture contents were transferred 
into 50ml falcon tubes and centrifuged at 1500 rpm for 10 minutes at four degree Celsius (°C). The 
supernatant was removed and aliquoted into cryovials and stored at -80°C pending usage. 
2.3 Result 
2.3.1 Site-directed Mutagenesis (SDM) of Mutants 
Eleven SDM reactions which consist of six single mutants SDM reactions and five combinations of double 
mutants and were introduced into a PKE04N TOPO clone. The following number of colonies were obtained 
from the SDM transformation reactions for each reaction (Table 2.10 and 2.11) 
Table 2.10: Colonies from single mutants SDM transformation reactions 








Table 2.11: Colonies from double mutants SDM transformation reactions 







2.3.2 Colony screening of the Mutants 
We picked four colonies at random for each of the transformation reaction, conducted colony PCR and 




Table 2.12: Colony screening of single mutants 
Mutants Number of colonies  
Screened  
Number of positive PCR 
product present 
A62V 4 3 
K65R 4 2 
S68G 4 4 
S68N 4 3 
S68D 4 4 
Y115F 4  4 
 
Table 2.13: Colony screening of double mutants 
Mutants Number of colonies  
Screened  
Number of positive PCR 
Product present 
K65R+A62V 4 4 
K65R+S68G 4 4 
K65R+S68N 4 4 
K65R+S68D 4 4 





Figure 2.4: Gel Electrophoresis of single mutants. Lane 1, 14 (1kb ladder), lane 2-5 (S68N), Lane 6-9 
(A62V), Lane 10- 13 (K65R) lane 15 (Negative control). 
 
 
Figure 2.5: Gel Electrophoresis of S68D single mutants. Lane 1 (1kb ladder) and lane 2-5 (S68D). 
 
Figure 2.6: Gel Electrophoresis of single mutants and DNA ladder. Lane 1 1KB ladder, lane 2-5 




Figure 2.7: Gel Electrophoresis of double mutants. Lane 1 1KB ladder, lane 2-5 (K65R_S68G), lane 
6-9 (K65_S68D) and lane 10 (K65R_Y115F). 
 
Figure 2.8: Gel Electrophoresis of double mutants. Lane 1 shows the 1KB ladder, lane 2-5 the 
K65R_A62V mutant, lane 6-9 the K65R_S68N mutant and lane 10 the Negative control. 
 
2.3.3. Sequencing of Mutants 
Sequencing was performed on all the colony positive for PCR products of the 11 SDM reactions performed.  
Seven of the mutant plasmids had the designated mutated sequence, while they remain four mutants that 
did not have the expected mutated sequence had the original sequence without the mutation. From the seven 
successful mutated sequences, all the six single mutants had the desired mutation. While only one of the 
double mutants had both the designated mutations present out of the five-double mutant SDM reactions 
carried out. See Table 2.15 and Figure 2.7(a-h) for the chromatogram peaks of the successful mutants 
generated. 
Table 2.14: Mutants with and without the designated mutated sequence. 
Mutants Designated mutated sequence  
A62V Present  
K65R Present  
S68G Present  
S68N Present  
S68D Present  
Y115F Present  
K65R+A62V Absent 
K65R+S68G Absent  
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K65R+S68N Present  
K65R+S68D Absent  
K65R+Y115F Absent 
 
A. PKE04N Wildtype 
PKE04N WT CAATATTTGCCATAAAAAAGAAGGACAGTACTAAGTGGAGA 
 
B. A62V 
Pke04n WT CAATATTTGCCATAAAAAAGAAGGACAGTACTAAGTGGAGA 




PKE04N WT CAATATTTGCCATAAAAAAGAAGGACAGTACTAAGTGGAGA 






PKE04N WT CAATATTTGCCATAAAAAAGAAGGACAGTACTAAGTGGAGA 
S68N  CAATATTTGCCATAAAAAAGAAGGACAATACTAAGTGGAGA 
 
E. S68D 
PKE04N WT CAATATTTGCCATAAAAAAGAAGGACAGTACTAAGTGGAGA 
S68D  CAATATTTGCCATAAAAAAGAAGGACGATACTAAGTGGAGA 
 
F. S68G  
PKE04N WT CAATATTTGCCATAAAAAAGAAGGACAGTACTAAGTGGAGA 





G. Y115F  
PKE04 WT TAGATGTGGGGGATGCATATTTTTCAGTTCCTCTAGATGAA 
Y115F  TAGATGTGGGGGATGCATTTTTTTCAGTTCCTCTAGATGAA 
 
H. K65R_S68N 
PKE04N WT CAATATTTGCCATAAAAAAGAAGGACAGTACTAAGTGGAGA 
K65R_S68N CAATATTTGCCATAAAAAGGAAGGACAATACTAAGTGGAGA 
 
Figure 2.9: The chromatogram peaks of the sequence traces. The underlined and highlighted base 
indicate the base change in comparison with the PKE04N WT, while the arrow on the chromatogram 
peaks indicate the designated base (a)PKE04 Wildtype, (b) A62V at position 200, (c)K65R at position 
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202, (d) S68N at position 213, (e) S68D at position 208 and 209, (f) S68G at position 205, (g) Y115F at 
position 350 and (h) K65R_S68N at position 198 and 207. 
2.3.4 Growth Kinetics of Mutants 
The mutants, as well as the wildtype viruses, were harvested when the percentage infectivity was between 
25 to 35% and kept at -80˚C pending when replication capacity assay (RCA) was carried out. As seen in 
Figure 2.10, the first virus to be harvested was the subtype B wildtype (pNL4-3) as it attained 56.59% 
infectivity on day seven, followed by the subtype C wildtype (PKE04N) and K65R on day eight with 
infectivity of 33.81% and 35.44 respectively. Viruses K65R+S68N, A62V and Y115F were harvested on 
day 11 with infectivity of 53.79%, 35.29%, and 45.23% respectively. Mutant S68D was harvested on day 
13 (40.37% infectivity). S68G and S68N did not achieve the needed infectivity and could not be used for 
subsequent experiments.  
Figure 2.10: Infectivity of mutants during co-transfection. The NL43Δ RT, PCR product of the mutant 
were co-transfected into CEM-GXR25 by electroporation and viral infectivity was monitored regularly 
till ~30% infectivity was attained. 
2.4 Discussion 
Studies have reported mutations “A62V, K65N, S68G/N/D, K70E/Q/T, L74I, V75L and Y115F” to be 
accompanying TDF resistance in subtype C, in addition to the preferentially selected mutation K65R 
(Maphumulo, 2016, Rhee et al., 2017, TenoRes-Study, 2016). However, their phenotypic impact on subtype 
C needed further investigation. In this chapter, we generated the most frequently observed mutations 
associated with TDF resistance: K65R, A62V, S68G/N/D, Y115F and combinations with K65R using 
SDM. In the SDM experiment, we observed the successful and efficient generation of single mutants 
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compared to the generation of the double mutants. The difference may have been due to the primer pair 
self-annealing. This could be eliminated by designing primers with the desired mutation inserted at four 
bases away from the 5′-end and a minimum of six to eight bases from the 3′-end, rather than the usual 10–
15 bases at each side (Zheng et al., 2004).  However, due to time constraints, this was not done in the current 
study but will be used for future experiments.  
For the single mutants generated (A62V, K65R, S68D, S68G, S68N, and Y115F), independent primers 
harbouring the designated mutation were used, whereas for the double mutants (K65R+A62V, 
K65R+S68D, K65R+S68G, K65R+S68N, and K65R+Y115F) primers designed to create the single 
mutants were used in combination in the site-directed mutagenesis reaction. However, we were not able to 
generate the desired combinations due to primer-dimer or as a result of the proximity of mutated positions 
(codon 62, 65 and 68). This is in line with earlier findings (Zheng et al., 2004, Weiner et al., 1994). 
Therefore, for the successful generation of double mutations, primers designed with both the mutations 
should have been utilized (Tian et al., 2010, Zheng et al., 2004). However, since K65R and Y115F are not 
close to each other, template switching during PCR may have been responsible (Abram et al., 2014, 
Nikolenko et al., 2004, Pathak and Temin, 1990). Also, it is possible that more colonies needed to be 
screened to detect the double mutants.  
In this study, the PCR products of the seven successfully generated mutants (A62V, K65R, S68D, S68G, 
S68N, Y115F, and K65R+S68N) and the pNL4-3 deleted RT were co-transfected and viral infectivity was 
monitored until about 30% infectivity was attained and then harvested. Seven out of the nine recombinant 
mutants attained the expected infectivity and successfully yielded viral replicating stock within the limited 
time (31 days), while two of the mutants (S68G and S68N) did not attain the expected infectivity and could 
not be used for subsequent experiments. This failure may be an indication that these mutations come with 
a fitness cost, resulting in a non-infectious virus.  This is in line with earlier findings by Garcia-Lerma et al 
(2000) and others who found that S68G came with a fitness cost and that S68G/N are secondary mutations 
that do not acquire resistance directly; rather, they are found in association with other mutations (García-
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Impacts of Tenofovir Selected Resistance Mutation of HIV-1 Subtype C on Replication 
Capacity and Drug Susceptibility 
3.1 Introduction 
South Africa, in line with World Health Organization (WHO) ART treatment guidelines for adult HIV-1 
infection, introduced the use of tenofovir (TDF) for “first-line antiretroviral treatment” and for “pre-
exposure prophylaxis” following its universal approval, due to its profound benefits over stavudine (d4T) 
which is toxic (Bennett et al., 2008, NDOH, 2014, WHO, 2013). Currently, the South African national 
treatment program first-line regimen consists of TDF/zidovudine (AZT) and lamivudine (3TC) or 
emtricitabine (FTC) if there are contraindications and efavirenz (EFV) or nevirapine (NVP) for pregnant 
women used as a fixed-dose combination. While the second-line regimen consists of AZT/TDF and 3TC 
or FTC and 1 protease inhibitor(PI) with ritonavir(r) as a booster (lopinavir (LPV/r) or atazanavir (ATV/r) 
(NDOH, 2014). The TDF can also be used for second-line treatment, as long as it antiretroviral activity is 
still maintained, preceding the emergence of the resistant virus after previous treatment exposure   (Rhee et 
al., 2017).  
However, the efficacy of the drug can be jeopardized by the evolution of drug resistance mutations. The 
TDF resistance can be acquired through the K65R or K70E mutation pathway (though less frequently) 
under TDF selection pressure (TenoRes-Study, 2016, Rhee et al., 2017, HIVBD, 2019). The K65R mutation 
prevalence ranges from below 20% in Europe and North America to more than 50% in sub-Saharan Africa 
(TenoRes-Study, 2016). Tenofovir is currently used as a first-line regimen in many countries including 
South Africa, where the predominant subtype is subtype C, have documented a high rate of the K65R 
resistance mutation in TDF treated patients (Skhosana et al., 2015, Sunpath et al., 2012) although a low 
prevalence of the K65R mutation has also been reported (Hoffmann et al., 2013). Furthermore, increasing 
levels of transmitted drug resistance or pre-treatment drug resistance in ART-inexperienced individuals in 
South Africa with K65R have been documented (Steegen et al., 2016). 
Furthermore, K65R causes broad resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and is 
one of the major factors responsible for virologic failure in patients on a triple nucleoside regimen not 
containing zidovudine (Margot et al., 2002, Shafer, 2002). K65R also occurs in combination with other 
mutations that increase TDF resistance such as, “A62V, S68G/N/D, K70E/Q/T, L74I, V75L, and Y115F”. 
These mutations were frequently observed in patients on a TDF regimen and were higher in subtype C 
compared to subtype B (Margot et al., 2016, Rhee et al., 2017). However, in the absence of these 
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accompanied mutations, it causes intermediate resistance to TDF (Margot et al., 2016, Miller et al., 2004, 
Skhosana et al., 2015, Stone et al., 2004, Svarovskaia et al., 2008).  
In this chapter, we investigated the impact of selected TDF resistance mutations of HIV-1 Subtype C with 
a focus on K65R, A62V, S68D, Y115F and K65R+S68N on viral replication capacity and drug 
susceptibility. 
3.2 Materials and methods 
3.2.1 Mutant selection 
The Quick-change Multi site-directed mutagenesis kit (Agilent) was employed to generate the following 
mutations K65R, A62V, S68D, Y115F and K65R+S68N as described in chapter two section 2.2.7.3. These 
mutants successfully yielded replicating virus stocks and were used for replication and drug susceptibility 
testing. 
3.2.2 Replication Capacity Assays (RCA) 
3.2.2.1 Virus titration  
Virus titres were performed in triplicate for each of the chimeric viruses generated. Titres served to 
determine the amount of virus needed to obtain a multiplicity of infection (MOI) of 0.3% on day two of a 
replication capacity assay (Brockman et al., 2007). Briefly, a total of 1 million GXR cells in 100 μl of R10 
was placed in each well of a 24 well culture plate (Corning Costar) followed by the addition of 400 μl of 
the harvested virus. The culture plate was incubated at 37ºC and 5% CO2 for 24 hours. The following day, 
one ml of pre-warmed R10 was placed in each well and the plate was again incubated at 37ºC and 5% CO2 
for 24 hours. On day two, the contents of each well were thoroughly mixed and 500 μl of culture was 
removed and prepared for flow cytometry, to measure the percentage of cells infected. The percentage of 
cells infected was used to calculate the amount of virus required to achieve 0.3% on day two of the 
replication capacity assays. The formula used was as follows:  
The volume of virus needed for the RCA (μl) = (0.3% ÷ % of cells infected on day 2 of the titre) *400 μl 
3.2.2.2 Replication Capacity Assay  
Replication capacity assays (RCA's) were conducted in GXR cells over a timeframe of seven days to 
determine the exponential growth of the virus as earlier described (Miura et al., 2009, Brockman et al., 
2007). Each assay was performed in triplicate for each of the recombinant viruses generated and in duplicate 
in an independently repeated experiment. Each assay included a negative control (GXR cells only) and 
positive control (pNL43-WT virus). 
55 
 
Briefly, a total of one million GXR cells in 100 μl of R10 was added to each well of a 24 well culture plate 
(Figure 3.1). The required amount of virus (i.e. amount obtained from the viral titration step) was diluted 
in R10 to obtain a final volume of 400 μl. The diluted virus was added to the various wells of the 24 well 
culture plate and then incubated at 37ºC and 5% CO2 for 24 hours. The following day, one ml of pre-
warmed R10 was added to each well and incubated for 24 hours again. Thereafter from day two to six, 
500μl of culture was removed daily to measure infectivity by flow cytometry and replenished with 500μl 
fresh pre-warm media. 
To determine the viral replication capacity, the exponential increase in percentage infected cells from day 
two to six post-infection was calculated using the semi-log method in Microsoft Excel. Then the “logest” 
function in Excel was employed to estimate the log10 exponential curve, with the best fit to the data. The 
value obtained represents the slope of the curve, and then transformed to its’ natural log. All replication 
values were normalized by dividing the slope of the exponential growth of each virus by the slope of the 
exponential growth of the pNL43-WT reference strain. Triplicate slope values were averaged. 
      
      
      
      
Figure 3.1: Representation of a plate layout for the Replication Capacity assay. NEG: Negative 
 
3.2.3 Phenotypic Drug Susceptibility Testing 
Phenotypic drug susceptibility assays were conducted to determine the drug susceptibility of five selected 
mutants. The TDF drug was used (gotten from the AIDS Research and Reference Reagent Programme, 











































susceptibility assay was employed and viral titres were also performed using the same assay as previously 
reported (Montefiori, 2009). 
3.2.3.1 TZMBL cells preparation 
TZMBL cells are a luciferase reporter-based HeLa cell line. They are adherent cells that express CD4 and 
CCR5 receptors and encode a luciferase gene which is regulated by the HIV-1 promoter. They are 
replication-competent and infected cells are detected by luminescence. TZMBL cells were gotten from the 
AIDS Research and Reference Reagent Programme, Division of AIDS, NIAID, NIH.  
An aliquot of TZMBL cells (one ml) was taken from a liquid nitrogen freezer and quickly put in a water 
bath at 37ºC. The cells were transferred to a 15 ml falcon tube containing 10 ml of pre-warmed Dulbecco’s 
Modified Eagle’s Medium (DMEM; Sigma), supplemented with 10% FBS (Gibco), 50 U/ml penicillin-
streptomycin and 10 mM HEPES. The 15 ml falcon tube was centrifuged at 1,200 rpm for 10 minutes. The 
supernatant was discarded, pellets were re-suspended in fresh DMEM (five ml) and transferred to a T25 
flask containing an additional five ml of DMEM. The T25 flask was incubated at 37ºC and 5% CO2 for 48 
hours. After 48 hours, cells were visualized using a Zoe® fluorescent imager (Bio-Rad). If cells were not 
80% confluent, media was discarded and replenished with fresh pre-warmed DMEM. If cells were 80% 
confluent, they were counted and used in experiments or passaged.  
Cells were counted by first detaching them from the monolayer. This was done by decanting culture 
medium from the flask, quickly washing the monolayer with sterile PBS and gradually adding 2.5 ml of 
0.25% trypsin-EDTA (Sigma) to the cell monolayer. The flask was incubated at room temperature for two 
minutes, followed by the removal of trypsin-EDTA and further incubation at 37ºC and 5% CO2 for four 
minutes. Thereafter, 10 ml of pre-warmed DMEM was added and the wall of the T25 flask, containing the 
cell monolayer, was repeatedly rinsed to detach cells. The content of the flask was thoroughly mixed. Cells 
were counted by adding 10 μl of thoroughly mixed cell culture to 10 μl of trypan blue (Bio-Rad, Hercules, 
USA). A total of 10 μl of this mixture was inserted into a TC20 cell counting slide (Bio-Rad) which was 
then loaded into a TC20 automated cell counter (Bio-Rad). The output of the TC20 cell counter was the 
cell concentration (i.e. cells/ml). The volume of cell culture used to obtain a required number of cells was 
calculated as follows:  
Volume of cell culture (ml) = number of cells required ÷ cell concentration (cells/ml)  
The number of cells required was removed and used in experiments, whilst the remaining cells were 
maintained at 250,000 cells/ml in DMEM in a T25 culture flask, incubated at 37ºC and 5% CO2. Cells were 
57 
 
monitored by microscopy, fed and passaged every 48 hours. Cells were maintained for a maximum of one 
month, after which time a new aliquot of cells was prepared for use in experiments.  
3.2.3.2 Single-cycle virus titration  
A single-cycle infection assay as previously reported (Montefiori, 2009) was conducted in the no drug 
medium, to measure the amount of virus required to achieve the average 50% tissue culture infective dose 
(TCID50) of each virus. Virus titrations were set up in a 96 well tissue culture plate (Corning Costar). A 
total of 100 μl of DMEM was placed in all wells of the plate. Then, 25 μl of virus (generated in 3.2.2) was 
transferred to the first 4 wells (column 1, rows A-D for one virus and rows E-H for a second virus). A five-
fold serial dilution was then performed. All wells of column 12 were virus-free; this served as the cell 
control. A total of 10,000 TZMBL cells in 100 μl of DMEM and 0.05 g/μl of diethylaminoethyl-dextran 
hydrochloride (DEAE dextran; Sigma) was added to all wells. The plate was then placed in the incubator 
at 37ºC and 5% CO2 for 48 hours. Following incubation, 100 μl of culture medium was pipetted out from 
each well and 100 μl of Bright Glo luciferase reagent (Promega) was added. The plate was allowed to stay 
at room temperature for two minutes, the contents of wells were thoroughly mixed and 100 μl of culture 
from each well was transferred to corresponding wells of a 96 well black solid bottom microplate 
(Promega). Luminescence (i.e. indicator of infectivity) was measured using the Victor Nivo multimode 
microplate reader ((Perkin-Elmer). 
Data are expressed as relative light units (RLUs) and positive infection was quantified using a cut-off of 
2.5 times that of the control RLU. The TCID was calculated by selecting the dilution that yielded 150,000 










Figure 3.2: Virus titration plate setup. Virus 1 (row A-D) virus 2 (rows E-H). CC, Cell control wells 
(cells only). 
3.2.3.3 Single-Cycle Phenotypic Drug Susceptibility Assay  
A single-cycle phenotypic assay was performed. The drug concentrations for TDF used in this study ranged 
from 50 μM to 0.39 μM. Each assay comprised of a cell control (cells only, no virus or drug), a virus control 
(virus and cells only, no drug) and virus experiments (virus, cells, and drug).  
Briefly, 10,000 TZMBL cells (in 100 μl of DMEM, 0.05 g/μl of DEAE dextran) and two-fold serial 
dilutions of TDF drug was infected with the relevant amount of virus that yielded 150,000 RLU equivalents 
(+/- 15,000 RLU), in a 96 well culture plate. The plate was placed in the incubator for 48 hours at 37ºC and 
5% CO2. After which, 120 μl of supernatant was removed and 100 μl of Bright Glo reagent added. The 
plate was allowed to stay for two minutes at room temperature. Thereafter, the contents of each well were 
mixed and transferred to corresponding wells of a black solid bottom microplate. HIV-1 infection was 
determined by luciferase expression via the Victor Nivo multimode microplate reader ((Perkin-Elmer). 
The extent to which the drug inhibited viral replication (i.e. percentage inhibition) was determined as the 
ratio of the difference in RLUs between the test wells and the cell control wells (i.e. negative/cells only) 
and the difference between the virus control wells (i.e. virus without exposure to drugs) and the cell control 
well and multiplying the result by 100 for each virus. The calculation is given below:  
%inhibition = (test wells – cell control wells) ÷ (virus control wells – cell control wells) * 100 
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The concentration of drug needed to prevent viral replication by 50% (i.e. IC50) was calculated by fitting 
the percentage inhibition results to a sigmoidal dose-response curve (with a variable slope) in GraphPad 
Prism.  
Fold change in drug susceptibility (i.e. differences in the amount of drug needed to obtain the IC50 between 
the mutant virus and a reference virus) was calculated by dividing the IC50 of each virus by the IC50 of the 
NL43-WT reference strain.  
3.2.3.4 Phenotypic Drug Susceptibility Interpretation 
For this study, three classifications of drug susceptibility were used to group the mutant viruses these 
included: susceptible (S), reduced susceptibility (RS) and resistance (R). For viruses to be considered as 
susceptible, their FC was required to be below the lower FC cut-off established in literature. To be grouped 
as having reduced susceptibility the FC values were required to be greater than the lower FC cut-off level. 
In this study we use 1.4 lower FC cut-off level for TDF based on published lower clinical cut-off (CCO) as 
reported in the literatures (Lu et al., 2002, Miller et al., 2004, Parkin et al., 2004b, Whitcomb et al., 2003, 
Winters et al., 2008, Murray et al., 2008, Margot et al., 2015) as well as in the Monogram assay. 
Table 3.1: TDF susceptibility clinical cut-offs 
 Fold Change 
Susceptibility (S) <1.4 
Reduced susceptibility (RS) 1.4-4.0 
Resistance (R) >4.0 
 
The drug susceptibility of each mutant virus was measured in triplicate using TDF. Replicate assays were 
performed at least two days apart in independently repeated experiments. 
3.2.4 Statistical Analyses 
GraphPad Prism version 5.0 software (La Jolla, CA, USA) was employed for all the statistical analyses 
performed.  To determine variations between the wild-type and the mutants a one-way Analysis of Variance 
(ANOVA) with Tukey post hoc testing was conducted. To evaluate agreement concordance between data 
either a Pearson’s correlation test or a Spearman’s Rank correlation test was applied to identify correlation 
coefficient (r) values. Student T-test was used to compare data between any two groups. A p-value of <0.05 




3.3.1 Viral Replication Kinetics 
CEM-GXR25 cells were infected with viruses harbouring drug resistance mutations and compared to those 
infected with the wild-type. The course of infection was followed daily over seven days. Viral replication 
kinetics as determined by daily FACS analysis (Figure 3.3). There were no significant differences 
(P=0.3360) in the replication kinetics between the wildtypes and the mutants as shown in Figure 3.3. We 
observed from day two to four of the assay, the mutants, as well as the wildtype viruses, grew relatively 
slowly, however, S68D and the wildtype viruses grew exponentially on day five, while K65R, K655+S68N, 
A62V, and Y115F grew exponentially on day six. The mutant S68D had the highest growth rate, both 
wildtype controls as well as, K65R had similar growth rates on day six, while Y115F had the lowest growth 
rate on day six (Figure 3.3). 
Figure 3.3: Replication kinetics of mutant viruses. 
3.3.2 Validating reproducibility of the replication assay 
Each replication assay was conducted in triplicate and repeated (duplicate) at least three days apart. All 
replication capacity values were normalized to the growth of pNL4-3 WT. Spearman’s correlation of the 
duplicate assays showed concordance of replication capacity between replicates (Spearman’s correlation 




Figure 3.4: Comparison of duplicated replication assays. Pearson’s correlation showed a high 
concordance between the two data sets indicating reproducibility of the assay. 
3.3.3 Replication capacity of chimeric HIV variants 
The replication capacity assay measures the competency of a virus to replicate, determined by the 
percentage GFP positive infected cells over seven days.  In this study, we determine the relative replication 
capacity of the TDF selected variants (A62V, K65R, S68D, Y115F, and K65R+S68N) generated by site-
directed mutagenesis in a multi-cycle parallel assay. Viral replication capacity was determined as the slope 
of the log GFP+ cells measured in the kinetics experiments. In this experiment, a replication capacity of 
one (1) represents the wild-type reference virus (Figure 3.5). There were significant differences (p<0.001) 
in the viral infectivity between the wildtypes and the mutants as shown in Table 3.2 and Figure 3.5. Viral 
infectivity was normalized to pNL4-3 for all variants and ranged from 0.86 to 1.05. Mutant K65R_S68N 
had the highest infectivity while subtype C wildtype (PKE04N) and A62V had the lowest (Figure 3.5). 
K65R mutation in combination with S68N displays a significantly higher replication capacity compared to 








Figure 3.5: Replication capacity of mutant viruses. CEM-GXR25 cells were infected in triplicate with 
the virus variants and evaluated with the wild-type. The infectivity rate was measured as the slope of 
log GFP+ cells analysed in the kinetics experiments. 
Table 3.2: Replication capacity relative to the wildtypes 
  Tukey's Multiple Comparison Test 
Significance p-value 







Subtype-B wildtype (pNL4-3) - - - - 
Subtype-C wildtype (PKE04) 0.86 ± 0.025 *** - - 
A62V 0.86 ± 0.021 ** ns - 
K65R 0.88 ± 0.02 ** ns - 
S68D 1.04 ± 0.002 ns *** - 
YII5F 0.87 ± 0.06 ** ns - 
K65R+S68N 1.05 ± 0.03 ns ** *** 





Figure 3.6: The effect of K65R and K65R+S68N on replication capacity. The student’s t-test between 
the two-group showed a significant difference (p<0.0010). 
3.3.3.1 Number of mutations in the sequence versus replication capacity 
In this study, the mutants were grouped into two classes based on the number of nucleotides change in the 
sequence; single nucleotide change mutants (A62V, K65R, and Y115F, class 1) and double nucleotide 
change mutants (S68D and K65R+S68N, class 2). All class 1 mutant viruses displayed lower replication 
capacity (RC) ranging from 0.86-0.88 compared to the wildtype (WT), while class 2 mutants viruses had 
similar RC as the WT, ranging between 1.04 and 1.05 (Figure 3.7). This study showed significant 
differences (p<0.0016) between class 1 and class 2 viruses.  Class 1 mutant viruses had similar RC as the 
subtype C WT, whereas class 2 was similar to that of the Subtype B WT (Figure 3.8). Also, class1 viruses 
are less fit than class 2 viruses.  Furthermore, the correlation between the number of nucleotide mutation in 
the sequence and replication capacity was assessed. The number of nucleotide mutation in the sequence 
correlate well with Replication Capacity, however not statistically significant (Figure 3.9). Data showed 
that the number of nucleotide change may impact on replication capacity and viruses with an increase in 
nucleotide change in the sequence may likely be associated with high RC.  Also, Variants at RT codon 68 
(S68D and S68N in combination with K65R) had RC values of 1.04 and 1.05 respectively. This suggests 





Figure 3.7: Comparison of replication capacity based on the number of nucleotides change in the 
sequence. Class 1(single nucleotide mutation virus); Class 2 (double nucleotide mutation virus). 
Mann Whitney test between the two classes showed a significant difference (p<0.0016). 
 
Figure 3.8: Comparison of the replication capacity of variants to the wildtype. Student’s t-test 





Figure 3.9: Correlation of the number of nucleotides change in the sequence with replication capacity. 
Pearson correlation (r) and p-value were calculated as shown. Results displayed a significant 
correlation between the number of nucleotides change in the sequence and replication capacity. 
3.3.4 Phenotypic Drug Susceptibility 
3.3.4.1 Correlation of Replication Capacity and IC50 
No correlation between replication capacity and IC50 was observed for the mutant viruses phenotyped with 
TDF. This indicated that IC50 was independent of replication capacity (Figure 3.10). 
 
Figure 3.10: Correlation of IC50 with replication capacity for mutant viruses treated with TDF. 
Spearman correlation (r) and p-value were calculated as shown. No correlation between IC50 and 





3.3.4.2 Number of nucleotide mutations in the sequence and IC50 for TDF. 
 
Figure 3.11: Comparison between the number of nucleotides introduced in the sequence and IC50 
for TDF. Spearman’s correlation showed no significant correlation between the number of 
nucleotides introduced in the sequence and IC50 for TDF. 
3.3.4.3 Phenotypic drug susceptibility profiles of TDF selected recombinant Mutants  
Five mutant viruses, as well as subtype B and C wildtypes, were used in the phenotypic drug susceptibility 
assay. The FC in IC50 and associated standard deviation, for TDF, is provided for each virus. Also, the 
susceptibility profile of each virus is provided, where S represents susceptible viruses and RS represents 
viruses with reduced susceptibility (Table3.3 and Figure 3.12). The cut-off value for TDF is highlighted in 
section 3.2.3.4 and Table 3.1. Of the five mutants phenotyped only, two displayed reduced susceptibility to 
TDF (K65R and K65R+S68N and three mutants (A62V, S68N, and Y115F) were susceptible to TDF (Table 
3.3 and Figure 3.12). Also, the dose-response curves corresponding to the susceptible HIV-1 subtype B 







Table 3.3: Overview of IC50 and FC of TDF for HIV-1 RT selected variants. 
Variants TDF Susceptibility profile 
 Mean IC50 (μM) ± SDa Fold change (FC) ±SDb  
Subtype-B wildtype:  
pNL4-3 
3.77 ± 0.05 1 S 
Subtype-C wildtype: 
PKE04N 
3.20 ± 0.47 0.86 ± 0.51 S 
A62V 2.06 ± 0.01 0.55 ± 0.04 S 
K65R 7.97 ± 0.25 2.13 ± 0.30 RS 
S68D 2.80 ± 0.13 0.70 ± 0.08 S 
Y115F 4.66 ± 0.22 1.23 ± 0.18 S 
K65R+S68N 6.84 ± 0.3 1.83 ± 0.35 RS 
a The  IC50 (50% inhibitory concentration) values were estimated by calculating inhibition of luminescence in Tzm-
bl cells. Values are averages ± standard deviations from at least two independent experiments of triplicates. b Fold 
change in IC50 compared with the wild type. Average fold change was calculated by the average fold of the fold 
change (mutant versus wildtype) calculated of each replicate assay. Abbreviations: FC – fold change; RS – reduced 
susceptibility; S – susceptible; SD – standard deviation. 
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Figure 3.12: TDF susceptibility profiles (A-K). Dose-response curves of the susceptible subtype B 
wildtype (pNL4-3) (blue), subtype C wildtype (PKE04N) (green) and to the mutant (red) are shown. (Doses 
in µM in the x-axes). IC50 values were determined using a sigmoid dose-response curve with variable slope 
(GraphPad Prism, version 5.0), and fold change (FC) values were determined by dividing the IC50 of the 
mutant by the wildtype IC50 for TDF. 
3.4 Discussion  
Various studies have investigated the impact of the TDF resistance mutations on replication capacity and 
drug susceptibility in HIV-1 subtype B as well as in Subtype C with more emphasis on K65R. In those 
studies, K65R showed a RC ranging from 0.20 to 0.82 relative to the WT virus (Miller, 2004b, Miller et 
al., 2004, Xu et al., 2015, Xu et al., 2009, Cong et al., 2007, Dapp et al., 2013) and FC of 1.7 to 5.0 in TDF 
susceptibility (Wainberg et al., 1999, Srinivas and Fridland, 1998, Rhee et al., 2006, Li et al., 2013b, Miller 
et al., 2003, Kagan et al., 2007, Lanier et al., 2004, Vermeiren et al., 2007). Recent studies have found more 
drug resistance mutations: “A62V, K65N, S68G/N/D, K70E/Q/T, L74I, V75L, and Y115F” in patients 
receiving TDF treatment. These mutations are often in association with K65R and are frequently seen in 
subtype C (Maphumulo, 2016, Margot et al., 2016, Rhee et al., 2017, TenoRes-Study, 2016). Therefore, it 
was necessary to investigate their phenotypic effects.  
In this chapter, replication capacity was measured for five mutants (A62V, K65R, S68D, Y115F, and 
K65R+S68N) generated by site-directed mutagenesis. These mutants were selected as they were more 
frequently associated with TDF resistance in patients receiving TDF based regimen and also yielded 
replication-competent viruses. These mutations were evaluated for their impact on replication capacity and 
drug (TDF) susceptibility in an HIV-1 subtype C virus. 
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Replication capacity and drug susceptibility profile of HIV-RT selected resistance variants to TDF 
The A62V mutant showed reduced replication capacity compared to the WT virus. This is in line with 
previous studies (Maldonado and Mansky, 2018, Dapp et al., 2013). Although in this study, the reduced 
RC was somewhat higher (0.86 fold) compared to previous studies reports (0.67 and 0.57-fold) (Dapp et 
al., 2013, Maldonado and Mansky, 2018). These differences may have been due to subtype variation. Also, 
A62V showed increased susceptibility (0.55-fold change) to TDF. This finding supports the argument that 
A62V does not confer resistance to TDF (Cases-Gonzalez et al., 2007, Maldonado and Mansky, 2018). 
The K65R mutation has been well characterized in both subtype B and C viruses (Deval et al., 2004, Miller, 
2004a, Miller et al., 2004, White et al., 2002, Xu et al., 2009, Xu et al., 2015). In this study, K65R mutation 
displayed reduced RC (0.88) compared to the WT virus. This outcome is similar to previous findings 
(Svarovskaia et al., 2008); however, other studies reported that the K65R mutation had the same replication 
capacity as the wild-type virus (García-Lerma et al., 2003, Gu et al., 1994b). In addition, lower RC values 
(range 0.24 to 0.60 relative to the WT virus)  have also been reported (Xu et al., 2015, Xu et al., 2009, Cong 
et al., 2007, Dapp et al., 2013) than that obtained in this study.  
Several approaches have been employed to determine HIV-1 replication capacity (Quinones-Mateu, 2001, 
Quinones-Mateu and Arts, 2002, Quinones-Mateu and Arts, 2006), oftentimes with varying outcomes as a 
result of the type of assay utilized to evaluate viral replication. A study using primary HIV-1 isolates have 
likewise demonstrated reduced replication in viruses harbouring the K65R mutation (Weber et al., 2005). 
In this study, however, we used pol recombinant viruses (based on site-directed mutagenesis) as previously 
described to determine the implication of this mutation on replication capacity (Brockman et al., 2007, 
Brockman et al., 2006). Furthermore, a clinical study has reported a reduction in the viral replication 
capacity in patients harbouring K65R mutation with the RC range of 0.20 to 0.82%, of the wild type (Miller, 
2004b, Miller et al., 2004). Also, studies have likewise demonstrated reduced replication with the K65R 
mutation using either single-cycle or competition assays (Deval et al., 2004, White et al., 2002). Therefore, 
discrepancies between the assay method or the impact of other mutations not found in this recombinant 
mutant virus may be attributed to the variation in the result obtained. Instead, one study has revealed that 
reduction in replication is primarily connected to the decrease intake of the nascent substrate by the K65R 
mutant RT (Deval et al., 2004).  
In addition, K65R mutation displays reduced susceptibility to TDF with a 2.1 FC relative to the WT virus. 
This is in line with previous studies who also found a 2.1 and 2.3 FC relative to the WT virus (Kagan et al., 
2007, Lanier et al., 2004). However, other previous studies reported highly reduced susceptibility to TDF 
with a fold change ranging from 3.0 to 5.0 (Wainberg et al., 1999, Srinivas and Fridland, 1998, Rhee et al., 
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2006, Li et al., 2013b). While Miller in 2003 reported a 1.7 fold change to TDF (Miller et al., 2003). These 
variations observed are possibly due to the reasons highlighted above. 
The mutant K65R+S68N in this analysis showed RC similar to the WT virus, while it displayed an increase 
in RC compared to K65R alone in the absence of the drug. A 1.8-fold decrease in susceptibility to TDF was 
seen for the double mutant, whereas K65R alone resulted in a 2.1-fold reduction in TDF susceptibility.  
This result is supported by (Melikian et al., 2012) who showed that K65R+S68N displayed a 1.9-fold 
reduction to TDF. However, higher fold change ranging from 2.8 to 3 have been shown by other studies 
(Rhee et al., 2006, Margot et al., 2015, Margot et al., 2006b).  
The S68D mutation exists as a polymorphism of RT at codon 68 and not much attention has been given to 
this mutation. In this study, S68D displayed an RC similar to the WT virus and a 0.74-fold change to TDF, 
as expected from a natural polymorphism. Our findings are in agreement with the previous findings on 
S68G (García-Lerma et al., 2000). Further studies will be needed to explain the effect of different amino 
acid variants at RT codon 68. To our knowledge, this is the first study to investigate S68D alone on 
replication capacity and susceptibility to TDF. 
The Y115F mutation is not frequently accompany drug resistance; it is found in about 10% of patients on 
abacavir (ABC) treatment alone and in 1% of patients on combination treatments. It has been observed to 
be found frequently in combination with the K65R, L74V, and M184V mutations (Stone et al., 2004, Miller 
et al., 2000).  In our investigation, we analysed the Y115F mutation alone, which showed a 0.87 replication 
capacity compare to the wild-type virus in the absence of TDF and a fold change of 1.23 in the presence of 
TDF. This outcome is similar to previous studies stating that Y115F has little impact on TDF susceptibility 
in the absence of K65R (Harrigan et al., 2000, Miller et al., 2000, Stone et al., 2004, Vermeiren et al., 2007, 
Lanier et al., 2004). In contrast, Ross and colleagues in 2006 reported that Y115F displayed a fold change 
of 1.8  to TDF (Ross et al., 2006). 
Number of nucleotides introduced in the sequence, replication capacity and TDF susceptibility 
In this present study, we assessed the implication of the number of nucleotides introduced in the sequence 
with replication capacity as well as with the FC in IC50 of TDF. The results displayed a significant 
correlation between the number of nucleotides introduced in the sequence and replication capacity. There 
was also no correlation between the number of nucleotides introduced in the sequence and susceptibility to 
TDF. Further, no correlation was observed between drug susceptibility and replication capacity implying 
that replication capacity cannot be used as a measure of treatment outcomes. 
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However, some of the effects of these mutations on RC might have been facilitated by the number of base 
(nucleotide) changes in the sequence as observed. In this study, mutants were classified into two groups 
(single nucleotide mutants and double nucleotide mutant) based on the number of nucleotide changes in the 
sequence. For example, the single nucleotide mutant viruses (A62V, K65R, and Y115F) had the lowest RC 
(0.86, 0.88 and 0.87) compared to that of the WT, whereas the double nucleotide change viruses (S68D and 
K65R_S68N) had RC (1.04 and 1.05) similar to the WT. This finding is in concordance with the previous 
report that resistant HIV-1 isolates with more nucleotide change may display high replication capacity 
under a condition where fitness is essential (Wain-Hobson and Morse, 1994); however, another study 
suggested that high nucleotide alteration was neither associated with reduced nor high fitness (Dapp et al., 
2013).  
3.5 Conclusion 
In this chapter, we described the impact of selected TDF resistance mutations on viral replication capacity 
and TDF susceptibility.  Mutant A62V, K65R, and Y115F viruses displayed reduced replicative fitness, 
suggesting that these less adapted viruses might be beneficial and better managed than wild-type viruses 
(Deeks, 2001, Quinones-Mateu, 2001). In addition, out of the five mutants analysed, three of the mutants 
(A62V, S68D, and Y115F) were susceptible to TDF and the mutants with K65R (K65R and K65R+S68N) 
had reduced susceptibility. Thus, additional investigations are needed to evaluate the effects of 




































Discussion and Conclusion 
4.1 Discussion 
In this study, we investigated the impact of TDF selected resistance mutations on replication capacity and 
TDF susceptibility on the HIV-1 subtype C virus. To have a better understanding of the impact of TDF 
selected resistance mutations, we first employed site-directed mutagenesis to generate the desired mutations 
of interest. These mutations were grouped into two: single resistance mutants (A62V, K65R, S68D, S68G, 
S68N, and Y115F) and double resistance mutant in combination with K65R (K65R+A62V, K65R+S68D, 
K65R+S68G, K65R+S68N, and K65R+Y115F. Furthermore, these resistance mutations were chosen as 
they were observed to be found frequently in patients on TDF treatment (Maphumulo, 2016, Margot et al., 
2016, Rhee et al., 2017, Shafer, 2017). All the single resistance mutants were successfully generated, while 
only one of the double resistance mutants (K65R+S68N) out of five was successfully generated.  Failure to 
generate these other double resistance mutants may be due to the nature of the primer used in this study. 
Single independent primers were used in combinations as opposed to the use of single independent primers 
harbouring the desired double mutations due to the proximity of the positions (codon 62, 65 and 68) (Zheng 
et al., 2004, Weiner et al., 1994). The following mutants: A62V, K65R S68D, Y115F, and K65R+S68N 
were successfully generated. We then analyse the effect of these mutants alongside the subtype B and C 
wild-types viruses on the replication capacity and TDF susceptibility.  
In our analysis of the replication capacity of TDF-selected mutant, we demonstrated that mutants with only 
one nucleotide base change in the sequence had significantly lower replication capacity relative to the WT 
virus than mutants with two/double nucleotide base change in the sequence as they are fitter. This 
observation is consistent with past findings, highlighting that resistant HIV-1 isolates with more nucleotide 
changes may be more adapted under a condition where fitness is favourable (Wain-Hobson and Morse, 
1994). In contrast, another study hypothesized that an increase in nucleotide change was neither associated 
with reduced nor high fitness (Dapp et al., 2013).  
The A62V mutation is situated in the finger region of HIV-1 RT, specifically in the flexible β3-β4 strand 
region and is usually observed in various mutational combinations such as the T69SSS insertion complex 
(Cases-Gonzalez et al., 2007) and the multi-dideoxynucleoside resistance (MDR) Q151M complex drug 
resistance (Shirasaka et al., 1995).  An earlier study revealed that A62V confers a slight reduction in 
replication capacity (Dapp et al., 2013); however, it does not cause resistance (Maldonado and Mansky, 
2018). Similarly, in this study, A62V displayed decreased replication capacity relative to the WT virus and 
also had the highest susceptibility to TDF. This observation confirmed the hypothesis that A62V does not 
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confer resistance to TDF on its own (Maldonado and Mansky, 2018). A62V has also been found to be 
associated with K65R (Margot et al., 2006a, Rhee et al., 2006, Rhee et al., 2017); however, we were 
unfortunately not able to do this analysis in this study. 
The K65R mutation is found in the conserved IKKK domain comprising of 12 nucleotide bases (ranging 
from codon 63 to 66) found in the finger’s subdomain of HIV-1 RT. The substitution of lysine (K) to 
arginine (R) at position 65 is said to be influenced by the movement resulting from the competition between 
the catalytic protein, the natural substrates and the RT inhibitors. Consequently, the correct substrate 
interaction or the successful phosphodiester bond generation of RT may be altered (Huang et al., 1998, 
Sarafianos et al., 1999b, Sarafianos et al., 2009). The mutant K65R has been reported to exhibit broad 
resistance to other NRTIs except for AZT (Deval et al., 2004, Margot et al., 2002, Wensing et al., 2017). 
In this study, K65R displayed a decrease in replication capacity (0.88) compared to the WT virus. This 
observation is similar to a previous report (Svarovskaia et al., 2008), while other studies have reported an 
even lower replication capacity relative to the WT virus compared to the value obtained in this study (Xu 
et al., 2015, Xu et al., 2009, Cong et al., 2007, Dapp et al., 2013). However, two studies have observed that 
there are no differences between the replication capacity of K65R and the wild-type virus (García-Lerma 
et al., 2003, Gu et al., 1994a).  
In this investigation, K65R exhibited reduced susceptibility to TDF. This is in alignment with past findings 
(Kagan et al., 2007, Lanier et al., 2004, Vermeiren et al., 2007). However, other studies have reported high 
resistance to TDF as opposed to this study (Wainberg et al., 1999, Srinivas and Fridland, 1998, Rhee et al., 
2006, Li et al., 2013b). Variations between assay techniques employed or the absence of other mutations 
not see in this recombinant mutant virus may give rise to these variations in the results obtained.  
Clinical studies have reported the combination of K65R and S68N (Margot et al., 2006a, Margot et al., 
2015, Rhee et al., 2006). In the present study, we explored the impact of K65R+S68N on replication 
capacity and TDF susceptibility. We observed that the K65R+S68N mutant had a considerably higher RC 
than the K65R mutant alone in the absence of TDF.  However, there was no significant impact on 
susceptibility to TDF between K65R+S68N and K65R alone. This was consistent with previous studies 
(Margot et al., 2006b, Roge et al., 2003, Svarovskaia et al., 2008). Our investigation confirmed the 
hypothesis that S68N may have a similar compensatory function as S68G regarding the replication capacity 
of the K65R mutant (Margot et al., 2015, Margot et al., 2006b, Svarovskaia et al., 2008). Although clinical 
studies have reported a higher FC to TDF (2.8 to 3.0) (Margot et al., 2006a, Margot et al., 2015, Rhee et 
al., 2006) compared to the FC (1.8) obtained in this study, the differences may be as a result of clinical 
isolates harbour other mutations not found in our recombinant viruses. K65R has been observed in 
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association with S68D in a few patients receiving TDF based treatment, although there is currently very 
little data available (Margot et al., 2016, Rhee et al., 2017, Shafer, 2017). 
The S68D mutation is found in the finger region of the flexible β3-β4 chain near to the polymerase hotspot 
of HIV-1 RT (Huang et al., 1998) and it is believed to be polymorphic. The current study was the first to 
investigate the impact of S68D on replication capacity and TDF susceptibility.  We showed that the S68D 
mutant displayed similar replication capacity as that of the wildtype B virus and was highly susceptible to 
TDF as anticipated of a natural polymorphism (García-Lerma et al., 2000). 
The Y115F mutation is situated in the polymerase catalytic site of the HIV-1 RT (Huang et al., 1998, 
Sarafianos et al., 2009) and the presence of Y115F mutation has been linked to alterations to the 
hydrophobic interactions in the RT functional position that affects the proper functioning of the polymerase 
(Ray et al., 2002). In our analysis, Y115F showed impaired replication capacity and slightly reduced 
susceptibility to TDF. This was consistent with past studies (Harrigan et al., 2000, Miller et al., 2000, Stone 
et al., 2004, Vermeiren et al., 2007, Lanier et al., 2004). This further supports the statement that Y115F has 
little impact on TDF susceptibility. However, another study did report reduced susceptibility to TDF (Ross 
et al., 2006). Difference between assay protocols used, the presence of other mutations found in clinical 
isolate or the effect of cART used in clinical isolates in contrast to the recombinant virus used in this study 
could have resulted in these variations of the findings. 
4.2 Conclusion 
In this study, we described the impact of TDF- selected mutations on replication capacity and TDF 
susceptibility.  Most of the viruses displayed diminished replicative fitness in the absence of TDF and were 
susceptible to TDF, except for K65R and K65+S68N which showed reduced susceptibility. Our findings 
support the hypothesis that TDF-selected mutations only confer a moderate decrease in TDF susceptibility 
(Shafer, 2017).  Hence, TDF may still be used for treatment in individuals harbouring these mutations alone, 
as its antiretroviral activity is still intact. 
4.3 Study limitation 
The inability to generate mutant viruses with single mutations in combination with K65R did not allow for 
the determination of the role of these as compensatory mutations in the presence of K65R. 
4.4 Recommendation for future studies 
 Further combinations of TDF drug-resistant HIV mutants need to be generated and their effect on 
replication capacity and drug susceptibility needs further investigation. 
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 Further study is required to determine how the number of nucleotide base changes (mutations) in 
the virus sequence can impact on viral fitness.   
 The effect of amino acid variants at codon 68 of HIV-1 RT on viral fitness and drug susceptibility 
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Primer sequences:  
 
Primer Name Primer Sequence (5' to 3') 
c68t_antisense 5'-tagtactgtccttcttttttatgacaaatactggagtgttatatgga-3'  
c68t_ 5'-tccatataacactccagtatttgtcataaaaaagaaggacagtacta-3'  
  
Oligonucleotide information:  
  
Primer Name Length (nt.) Tm Duplex Energy at 68 °C Energy Cost of Mismatches 
c68t_antisense 47  78.10℃  -41.71 kcal/mole  9.70%  
C68t_ 47  78.10℃  -45.52 kcal/mole  9.58%  
  







a a a t c c a t a t a a c a c t c c a g t a t t t g c c a t a a a a a a g a a g g a c a g t a c t a a g t  
   | | | | | | | | | | | | | | | | | | | | | | |  | | | | | | | | | | | | | | | | | | | | | | |  
3 ' - a g g t a t a t t g t g a g g t c a t a a a c a g t a t t t t t t c t t c c t g t c a t g a t - 5 '   
C68t_ 
5 ' - t c c a t a t a a c a c t c c a g t a t t t g t c a t a a a a a a g a a g g a c a g t a c t a - 3 '  
   | | | | | | | | | | | | | | | | | | | | | | |  | | | | | | | | | | | | | | | | | | | | | | |  
t t t a g g t a t a t t g t g a g g t c a t a a a c g g t a t t t t t t c t t c c t g t c a t g a t t c a   
 
Mutation: K65R 
Primer sequences:  
 
Primer Name Primer Sequence (5' to 3') 
a77g_ antisense 5'-cttagtactgtccttcctttttatggcaaatactggagtgttatat-3'  
a77g_ 5'-atataacactccagtatttgccataaaaaggaaggacagtactaag-3'  
  
Oligonucleotide information:  
  
Primer Name Length (nt.) Tm Duplex Energy at 68 °C Energy Cost of Mismatches 
a77g_ antisense 46  78.02℃  -40.70 kcal/mole  .09%  



















t c c a t a t a a c a c t c c a g t a t t t g c c a t a a a a a a g a a g g a c a g t a c t a a g t g g  
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  | | | | | | | | | | | | | | | |  
3 ' - t a t a t t g t g a g g t c a t a a a c g g t a t t t t t c c t t c c t g t c a t g a t t c - 5 '   
a77g_ 
5 ' - a t a t a a c a c t c c a g t a t t t g c c a t a a a a a g g a a g g a c a g t a c t a a g - 3 '  
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  | | | | | | | | | | | | | | | |  





Primer sequences:  
 
Primer Name Primer Sequence (5' to 3') 
g86a_antisense 5'-ctactaatttcctccacttagtattgtccttcttttttatggcaaat-3'  
g86a___ 5'-atttgccataaaaaagaaggacaatactaagtggaggaaattagtag-3'  
  
Oligonucleotide information:  
  
Primer Name Length (nt.) Tm Duplex Energy at 68 °C Energy Cost of Mismatches 
g86a_antisense 47  78.10℃  -40.55 kcal/mole  6.88%  
g86a___ 47  78.10℃  -45.22 kcal/mole  4.58%  
  







a g t a t t t g c c a t a a a a a a g a a g g a c a g t a c t a a g t g g a g g a a a t t a g t a g a t t  
   | | | | | | | | | | | | | | | | | | | | | | |  | | | | | | | | | | | | | | | | | | | | | | |  
3 ' - t a a a c g g t a t t t t t t c t t c c t g t t a t g a t t c a c c t c c t t t a a t c a t c - 5 '   
g86a_ 
5 ' - a t t t g c c a t a a a a a a g a a g g a c a a t a c t a a g t g g a g g a a a t t a g t a g - 3 '  
   | | | | | | | | | | | | | | | | | | | | | | |  | | | | | | | | | | | | | | | | | | | | | | |  




Primer sequences:  
 
Primer Name Primer Sequence (5' to 3') 
a85g_ antisense 5'-tactaatttcctccacttagtaccgtccttcttttttatggcaaata-3'  
a85g_ 5'-tatttgccataaaaaagaaggacggtactaagtggaggaaattagta-3'  
  




Primer Name Length (nt.) Tm Duplex Energy at 68 °C Energy Cost of Mismatches 
a85g_ antisense 47  78.10℃  -42.02 kcal/mole  3.70%  
a85g_ 47  78.10℃  -45.75 kcal/mole  3.70%  
  







c a g t a t t t g c c a t a a a a a a g a a g g a c a g t a c t a a g t g g a g g a a a t t a g t a g a t  
   | | | | | | | | | | | | | | | | | | | | | | |  | | | | | | | | | | | | | | | | | | | | | | |  
3 ' - a t a a a c g g t a t t t t t t c t t c c t g c c a t g a t t c a c c t c c t t t a a t c a t - 5 '   
a85g_ 
5 ' - t a t t t g c c a t a a a a a a g a a g g a c g g t a c t a a g t g g a g g a a a t t a g t a - 3 '  
   | | | | | | | | | | | | | | | | | | | | | | |  | | | | | | | | | | | | | | | | | | | | | | |  
g t c a t a a a c g g t a t t t t t t c t t c c t g t c a t g a t t c a c c t c c t t t a a t c a t c t a   
   
Mutation: S68D 
 
Primer sequences:  
 
 
Oligonucleotide information:  
 
Primer Name Length (nt.) Tm Duplex Energy at 68 °C Energy Cost of Mismatches 
a85g_g86a_antisense 54  78.20℃  -46.88 kcal/mole  7.98%  
a85g_g86a_ 54  78.20℃  -51.33 kcal/mole  6.47%  
  
 
Primer-template duplexes:  
  
Primer Name Primer-Template Duplex 
a85g_g86a_antisense 
c t c c a g t a t t t g c c a t a a a a a a g a a g g a c a g t a c t a a g t g g a g g a a a t t a g t a g a t t t c a  
   | | | | | | | | | | | | | | | | | | | | | | | | | |   | | | | | | | | | | | | | | | | | | | | | | | | | |  
3 ' - g t c a t a a a c g g t a t t t t t t c t t c c t g c t a t g a t t c a c c t c c t t t a a t c a t c t a a - 5 '   
a85g_g86a_ 
5 ' - c a g t a t t t g c c a t a a a a a a g a a g g a c g a t a c t a a g t g g a g g a a a t t a g t a g a t t - 3 '  
   | | | | | | | | | | | | | | | | | | | | | | | | | |   | | | | | | | | | | | | | | | | | | | | | | | | | |  





Primer sequences:  
 
Primer Name Primer Sequence (5' to 3') 
a227t_antisense 5'-catctaaaggaaccgaaaaaaatgcatcccccacatctaat-3'  





Primer Name Primer Sequence (5' to 3') 
a85g_g86a_antisense 5'-aatctactaatttcctccacttagtatcgtccttcttttttatggcaaatactg-3'  







Primer Name Length (nt.) Tm Duplex Energy at 68 °C Energy Cost of Mismatches 
a227t_antisense 41  78.60℃  -47.67 kcal/mole  .37%  
a227t_ 41  78.60℃  -45.52 kcal/mole  5.51%  
  
 







a g t a t t a g a t g t g g g g g a t g c a t a t t t t t c g g t t c c t t t a g a t g a a a  
   | | | | | | | | | | | | | | | | | | | |  | | | | | | | | | | | | | | | | | | | |  
3 ' - t a a t c t a c a c c c c c t a c g t a a a a a a a g c c a a g g a a a t c t a c - 5 '   
a227t_ 
5 ' - a t t a g a t g t g g g g g a t g c a t t t t t t t c g g t t c c t t t a g a t g - 3 '  
   | | | | | | | | | | | | | | | | | | | |  | | | | | | | | | | | | | | | | | | | |  





Appendix B: Ethics clearance certificate 
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